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Coenzyme A (CoA) is a cofactor essential to several metabolic processes, including central 
energy and fatty acid metabolism. In addition, there is increasing evidence that CoA also plays 
an important role in the rate of neurodegeneration and aging. CoA is usually biosynthesized 
from vitamin B5, but recently it was shown that dietary CoA can also replenish intracellular 
CoA levels through degradation of exogenous CoA by ecto-nucleoside pyrophosphatases into 
3',5’-ADP and 4'-phosphopantetheine (P-PantSH), which is subsequently taken up by cells. 
Importantly, permeability studies suggested that this uptake occurs by passive diffusion, an 
observation that was further confirmed by nutrient complementation studies in Drosophila S2 
cells containing a mutation that results in CoA depletion. Moreover, investigation of CoA 
homeostasis in Escherichia coli suggested that this bacterium irreversibly exports P-PantSH 
to regulate intracellular CoA levels. This suggests an interplay between eukaryotes and their 
microbiome regarding the maintenance of levels of this cofactor through the exchange of P-
PantSH as a likely nexus metabolite in CoA biosynthesis.  
In this study we used a systematic biophysical approach to investigate the determinants of P-
PantSH permeability, and whether this relates to the structure of the molecule, or a certain 
specific membrane composition. This was achieved by devising a new assay specific for 
determining the membrane permeability of thiolated metabolites (such as P-PantSH), and 
subsequently applying this assay in studying the permeability of P-PantSH and its structural 
analogues in model membranes. Our results indicate that the permeability of P-PantSH is 
dependent on the fluidity of the membranes in question, and that manipulation of membrane 
composition to affect membrane fluidity offers a new mechanism to regulate the maintenance 
of CoA levels from exogenous sources. Using the same assay, we were also able to study a 
mitochondrial solute carrier protein that is apparently involved in the regulation of CoA levels 
in the mitochondria. ADP-dependent efflux of P-PantSH was observed for the transporter, and 
this constitutes preliminary evidence of the implied role of P-PantSH as a nexus metabolite of 
CoA metabolism.  
These findings have important implications for the development of drugs that target CoA 
biosynthesis and utilization, whether in the context of human diseases for the treatment or 





Koënsiem A (KoA) is 'n kofaktor wat noodsaaklik is vir verskeie metaboliese prosesse, 
waaronder sentrale energie en vetsuurmetabolisme. Daarbenewens is daar toenemende 
bewyse dat KoA ook 'n belangrike rol speel in die tempo van neurodegenerasie en 
veroudering. KoA word gewoonlik gebiosintetiseer vanaf vitamien B5, maar onlangs is 
aangetoon dat KoA in die dieet ook intrasellulêre KoA-vlakke kan aanvul deur die afbraak van 
eksogene KoA deur ekto-nukleosied pirofosfatases na 3',5'-ADP en 4'-fosfopanteteïen (P-
PantSH), wat gevolglik deur selle opgeneem word. Meer belangrik, deurlaatbaarheidstudies 
het aangetoon dat hierdie opname plaasvind deur passiewe diffusie, 'n waarneming wat 
verder bevestig is deur voedingsaanvullingsstudies in Drosophila S2-selle wat 'n mutasie 
bevat wat tot die uitputting KoA-reserwes lei. Verder het die ondersoek na KoA-homeostase 
in Escherichia coli voorgestel dat hierdie bakterie P-PantSH onomkeerbaar uitvoer om 
intrasellulêre KoA-vlakke te reguleer. Dit dui op 'n wisselwerking tussen eukariote en hul 
mikrobioom t.ov. die handhawing van die vlakke van hierdie kofaktor deur die uitruil van P-
PantSH as 'n waarskynlike verbindingsmetaboliet in KoA-biosintese. 
In hierdie studie het ons 'n sistematiese biofisiese benadering gebruik om die determinante 
van P-PantSH-deurlaatbaarheid te ondersoek, en of dit verband hou met die struktuur van die 
molekule, of 'n spesifieke membraansamestelling. Dit is bewerkstellig deur 'n nuwe toets te 
ontwerp wat spesifiek is vir die bepaling van die membraandeurlaatbaarheid van tiol-
bevattende metaboliete (soos P-PantSH), waarna hierdie toets gebruik is vir die bestudering 
van die deurlaatbaarheid van P-PantSH en strukturele analoë daarvan in modelmembrane. 
Ons resultate dui aan dat die deurlaatbaarheid van P-PantSH afhanklik is van die 
vloeibaarheid van die betrokke membrane, en dat die manipulering van die 
membraansamestelling om die membraanvloeibaarheid te beïnvloed 'n nuwe meganisme 
bied om die handhawing van KoA-vlakke vanuit eksogene bronne te reguleer. Met behulp van 
dieselfde toets kon ons ook 'n mitochondriale vervoerproteïen bestudeer wat betrokke blyk te 
wees by die regulering van KoA-vlakke in die mitochondria. ADP-afhanklike uitvloei van P-
PantSH is waargeneem vir die vervoerproteïen, en hierdie resultaat vorm 'n voorlopige bewys 
van die implisiete rol van P-PantSH as 'n verbindingsmetaboliet van KoA-metabolisme. 
Hierdie bevindings het belangrike implikasies vir die ontwikkeling van medikasie wat KoA-
biosintese en -benutting teiken, hetsy in die konteks van menslike siektes vir die behandeling 
of vertraging van neurodegeneratiewe siektes, of alternatiewelik as antimikrobiese middels vir 
die behandeling van aansteeklike siektes.  
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1 Introduction and Literature Review 
1.1 Poor permeability is still a great barrier to overcome in drug discovery 
Before the 1970s drug discovery involved phenotype-based approaches which were very 
empirical1.  It was informed by published work, existing drugs and natural products. Screening 
techniques then involved lower through-put in vitro assays that required no understanding of 
molecular mechanisms of action, as well as in vivo phenotype assessments in which activity 
could be translated into therapeutic impact of a given disease state2. As a result, the drug 
discovery processes were inherently biased towards compounds that were soluble in aqueous 
conditions and were also bioavailable1.  This approach was very successful and produced 
most of the therapeutics still in use today2,3. Nonetheless, the drawback of this approach is 
that it is often challenging to optimize the molecular properties of candidate drug molecules 
as there is no prior knowledge of the molecular mechanisms of action2. Incorporating new 
technologies into this drug discovery approach is another challenge that is often encountered2.  
Advances in molecular genetics saw the evolution of drug discovery to become more target-
based2,3. With it came a shift towards protein targets with key roles in pathogenesis, as well 
as screening for compounds that interact with these targets4–6. Current drug discovery 
processes can therefore be summarised to consist of the following steps3: 
1. Basic research which involves target identification and selection 
 This is usually based on a hypothesis that inhibition of a certain protein or 
pathway will result in a therapeutic effect in a disease state. 
 A target is then selected and validated based on this hypothesis. 
2. Lead discovery and candidate selection 
 This involves an intensive search to find ‘drug-like’ small molecules or biological 
therapeutic agent also known as development candidates. 
3. Pre-clinical development 
 Identification of a “hit” compound which has the desired effect and the activity 
of which has been confirmed by further retesting. 
4. Clinical development 
5. Food and Drug Administration (FDA) filing 
The first two steps of this process involve screening of compounds for potential therapeutic 
properties. There are several approaches that can be used for this, and these include the 
following3: 
1. Knowledge-based screening7,8 
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 It involves selection of a small subset of molecules from a large chemical 
library. The selection is based on knowledge of the target protein, examples 
from the literature or on molecules of a similar class previously shown to 
possess the desired activity. 
2. Physiological screening 
 This is a tissue-based approach that looks for a response more aligned with 
the desired in vivo effect rather than targeting one specific molecular 
component. 
3. Fragment-based screening9  
 Involves the generation of small molecule libraries which are then screened at 
high concentrations as potential therapeutics. 
 This process is usually accompanied by generation of protein structures by 
structure-based tools such as X-ray crystallography and computational 
modelling. The chemical libraries are then screened against structures to 
identify potential “hits”. 
4. High-throughput screening (HTS)10 
 This is currently the most popular approach and involves screens of entire 
compound libraries directly against the drug target using more complex assay 
systems. 
HTS became more popular in the 1980s were the advent of technology brought with it 
automation, which encouraged the development of libraries of chemical compounds using 
combinatorial chemistry1,11.  This saw a shift in drug development strategies to focus more on 
optimization of binding affinity whilst overlooking binding kinetics and conformation of the 
potential drug molecule to the target. Therefore, more emphasis was placed on chemical 
functionalization to improve potency of the potential drug molecule towards the target rather 
than on solubility that would ensure drug bioavailability in vivo1.  
Despite their potency in vitro, it is now apparent that compounds which demonstrate poor 
solubility and bioavailability are unlikely to become drug molecules. It has also come to light 
that efficient membrane permeation maybe necessary for bioavailability12. Taken together, 
these suggest that solubility and permeability assessments may be crucial in identifying a 
potential drug molecule.  
Whilst studies or practices that focus directly on the permeability of potential drug molecules 
are scarce, guidelines like the Lipinski rule of five (Ro5) has served as good substitutes for 
predicting this property. Ro5 predicts the therapeutic potential of molecules, and does so in a 
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manner that takes into account their solubility and permeability characteristics. It stipulates 
that an ideal drug molecule should have the following features13:  
 5 or less hydrogen bond donors  
 a molecular mass of 500 or below  
 a calculated LogP of 500 or less 
 a sum of nitrogen and oxygen atoms (hydrogen bond acceptors) that is equivalent to 
10 or less’ 
Additionally, alternative metrics such as the polar surface area (PSA) were also developed to 
compliment the Ro512,14. Together these have been successfully applied in the evaluation of 
orally bioavailable drug molecules.  
Nonetheless, in the recent years, many of the FDA approved drug molecules were found to 
be non-Ro5 compliant. Therefore, it is evident that guidelines like the Ro5 cannot be 
interpreted in a literal, inflexible manner as that could stunt innovation in drug discovery1. 
Conversely, making it a more common practice to perform comprehensive enquiries into 
permeability of pontetial drug molecules may be more beneficial for drug discovery: Such 
enquiries will not only aid in understanding the mechanisms by which drug molecules 
permeate cells, but can also inform strategies for  mitigating poor permeability. This can in 
turn lead to the repurposing of lead compounds that were dismissed from clinical trial due to 
poor permeability. 
1.2 How do small molecules enter the cell? 
Small molecules of moderate polarity can readily cross membranes by passive diffusion15. For 
instance small non-polar gases can rapidly cross membranes with a high permeability 
coefficient of 3.5×10-1 cm.s-1 reported for CO₂16, whilst even slightly larger polar molecules like 
urea have lower permeability with a permeability coefficient of 1.35×10-6 cm.s-117. Conversely, 
larger molecules of relatively high polarity such as sugars and peptides to name a few, cannot 
permeate cells by passive diffusion but require transporter-mediated membrane permeation15. 
There are two modes of transporter-mediated cell entry, categorized according to their energy 
requirement as active transport and facilitated diffusion15. 
Active transport involves translocation of molecules against a concentration gradient and 




 Ion pumps: these proteins transport ions against their concentration gradients. An 
example thereof is the Na⁺/K⁺ ATPase which transports three Na⁺ ions into the cell, 
and two K⁺ ions out of the cell for every ATP molecule that is hydrolyzed18. 
On the other hand, facilitated diffusion involves transporter-mediated membrane translocation 
of molecules in the direction of their concentration gradient, and does not require external 
energy input15. Examples are: 
 GLUT transporter family: This group of transporters are responsible for 
transmembrane import of glucose, galactose and fructose19. 
 Ion channels: allow passive diffusion of inorganic ions with high specificity20. 
 Ionophores: bacteria can synthesize ionophores which facilitate the diffusion of ions 
across the membrane by complexing and shuttling ions21. 
 Aquaporins: facilitate the transport of water and hydrophilic solutes across the 
membrane22. 
In addition to these, some organisms also have dedicated efflux systems that are responsible 
for removal of toxins and other xenobiotics from the cells22. The most common of these is the 
ABC transporter family (e.g.: TolC pump) which is involved in the efflux of structurally diverse 
compounds23. 
1.2.1 The outer membrane of Gram-negative bacteria gives intrinsic resistance to 
antibiotics 
Membrane composition is a major determinant of the distinct permeability profiles observed 
for organisms. Membrane lipids are amphipathic molecules that self-assemble into 
supramolecular structures such as bilayers. The lipid bilayer is a functional barrier between 
subcellular compartments, and between the cell and its environment15,24.   
The following gives a brief description of the membrane composition of mammalian and 
bacterial cells with specific focus on the ability of Gram-negative bacteria to alter the 
permeability profile of the membranes as a line of defense against antibiotics and other 
molecules perceived as hostile towards the organism. 
1.2.1.1 Mammalian cells 
The plasma membrane is a dynamic bilayer with a thickness of about 5 nm, and is made up 
of multiple lipid species and membrane proteins15,24. The lipids are distributed asymmetrically 
in the bilayer and can be grouped into three main classes as follows: 
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 Glycerophospholipids (GPLs): These are made up of fatty acyl chains with a 
phosphatidyl ester attached to the terminal carbon. The phosphate ester group can 
either be an ethanolamine, choline, serine or inositol. The fatty acid chains range in 
size from 16-24 carbons, and can be saturated, mono- or poly-unsaturated25,26.  
 Sphingolipids: these are also phospholipids but with no glycerol backbone. Long fatty 
acyl chains combine with sphingosine to make up sphingolipids. Sphingosine is made 
from palmitoyl-CoA and serine25,26.  
 Cholesterol: this is a sterol type lipid which modulates the fluidity of a membrane over 
a range of physiological temperatures25. 
The best-studied model for eukaryotic membranes is the red blood cell membrane25,2728. It is 
characteristically asymmetric, with the outer leaflet enriched in sphingomyelin and 
phosphatidylcholine, and the inner leaflet in phosphatidylserine, phosphatidylethanolamine 
and phosphatidylinositol. Cholesterol is also enriched in the outer leaflet of these membranes.  
1.2.1.2 Bacterial cell envelope 
Gram-negative bacteria have a cell envelope made up of two membranes—a cytoplasmic and 
an outer membrane—separated by a layer of peptidoglycan, as well as a cellular compartment 
called the periplasm29. 
 Cytoplasmic membrane: This is generally a phospholipid bilayer heavily populated with 
membrane proteins. Unlike the mammalian plasma membrane, it is exclusively made 
of GPLs and has no sterols or sphingolipids26. The main functions thereof include 
nutrient import and export of toxins, as well as all membrane-related functions that 
would be associated with organelles in eukaryotic cells, the most notable of which is 
energy metabolism30. It also serves as barrier to hydrophilic and charged molecules 
this is especially the case in artificial membranes where protein transporters are 
absent. The E. coli cytoplasmic membrane consists of the following GPLs: 
phosphatidylethanolamine, phosphatidylglycerol and cardiolipin. Furthermore, the 
most abundant fatty acids in this organism include palmitic acid (16:0), palmitoleic acid 
(16:1) and vaccenic acid (18:1) – where (x:y) refers to chain length and number of 
unsaturated bonds, respectively31. 
 The outer membrane: It can be divided into outer leaflet largely made up of 
lipopolysaccharide (LPS), and the inner leaflet made up of  phospholipids31. 
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 The peptidoglycan layer: It is a cell wall that serves a rigid exoskeleton. Gram-positive 
bacteria, such as Staphylococcus aureus, do not have an outer membrane, but have 
a thick peptidoglycan layer which distinguishes it from Gram-negative bacteria30. 
 The periplasm: it consists of densely packed proteins and as a result is more viscous 
than the cytoplasm30,32. 
LPS constitutes the outer leaflet of the outer membrane of the cell envelope. This molecule is 
exclusively found in Gram-negative bacteria is an amphiphilic molecule which carries a 
negative charge at physiological pH. This in turn gives Gram-negative cells a relatively strong 
negative charge29. As result, the outer membrane is generally resistant to hydrophobic 
antibiotics, bile salts, detergents and other molecules perceived as hostile by the bacteria. It 
is therefore presumed that the outer membrane is responsible for the intrinsic resistance to 
antibiotics that is often observed in Gram-negative bacteria29,32,33. 
In addition to this, Gram-negative bacteria have elaborate efflux systems made up of tripartite 
structures that span the entire cross-section of the cell envelope34–36. These consist of a 
transporter protein located in the inner cytoplasmic membrane, an accessory protein located 
in the periplasmic space, and an outer membrane channel (Figure 1-1).  These effectively 
shorten the distance between the cytoplasm and the extracellular space, which in turn 
translate to efficient efflux rates. The most common example of these outer membrane 
channels is the TolC protein (Figure 1-1)37. These channels are promiscuous and can interact 
with a wide range of inner membrane transporters.  
Gram positive membranes do not have the outer membrane of LPS and phospholipids, and 
as a result also have a thin periplasm sandwiched between the cytoplasmic membrane and a 
thick layer of peptidoglycan. This difference in architecture make tripartite efflux systems found 
in Gram negative bacteria, unnecessary in Gram-positive bacteria. As such, Gram-positive 
bacteria lack the outer membrane channels which are constituents of the tripartite efflux 




Figure 1-1: The difference in membrane architecture necessitates tripartite efflux systems in Gram-
negative but not Gram-positive bacteria. Gram-negative bacteria have tripartite efflux systems that span the 
width of the cell envelope consisting of a transport protein, an accessory protein and the TolC efflux pump situated 
in the inner membrane, periplasm and outer membrane, respectively. Gram-positive organisms do not have the 
outer membrane and therefore lack the TolC efflux pump that is often associated with the intrinsic resistance of 
Gram-negative bacteria to antibiotics. Adapted from Piddock38. 
1.2.2 Drug molecules should ideally permeate molecules by passive diffusion 
Our current knowledge indicates that Gram-negative bacteria are inherently resistant to 
antibiotics as a result of poor permeability of the outer membrane. Moreover, the elaborate 
efflux systems on the cell envelopes of Gram-negative bacteria also make it easy for these 
organisms to acquire resistance to additional classes of antibiotics. Therefore, the ideal drug 
molecule against these organisms should be able to permeate the cell envelope, and having 
done so should remain unrecognizable to the efflux systems. This insaturable mode of entry 
would enable intracellular accumulation of the drug to concentrations which are sufficient to 
elicit the desired therapeutic effect. This suggests that the ideal drug molecule should 
preferably permeate the cell by passive diffusion. 
Passive diffusion refers to the movement of molecules across the cell membrane driven by 
ion or solute gradients16. This process is described as passive since there is no external 
energy input or output required to affect the transport.  
According to the solubility-diffusion theory, membrane translocation by passive diffusion 
occurs in a three-step process summarized as follows: first, the molecule partitions through 
the membrane, second it diffuses across the membrane, and third  it is finally released into 
the cytoplasm39,40. It further states that the permeability of a molecule directly relates to its oil-
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water partition coefficient as well as its molecular radius, the latter describing the measure of 
steric hindrance a molecule will encounter when crossing the bilayer39,40.  
1.2.2.1 Membrane fluidity modulates membrane permeation by passive diffusion 
The solubility-diffusion theory suggests a close relationship between membrane fluidity and 
permeability of a molecule39,40 It states that membrane fluidity influences permeability by 
determining the diffusion rate of the target molecule through the bilayer. Lower membrane 
fluidity will therefore result in low molecule permeability. This can be explained by the small 
aqueous filled cavities that form transiently in different regions of the bilayer. These include 
the interface between the phospholipid head groups and the aqueous medium, as well as the 
portion of the hydrocarbon chain that is adjacent to the head groups. According to the 
solubility-diffusion theory, solutes dissolve into the cavities and so permeate the membrane. 
Membrane regions with lower fluidity has less of these cavities, which in turn translate to lower 
solute permeability39,40.  
Membrane fluidity is in turn modulated by membrane composition: GLPs are the most 
abundant type of lipids in membranes, and its main components include two acyl (fatty acid-
derived) chains and a hydrophilic head group25,26,41.The head group generally determines the 
molecular geometry of the phospholipid, which in turn determines membrane fluidity, as shown 
in Figure 1-2. For example, lysophospholipids, which play a major role in signaling, adopt a 
conical geometry (Figure 1-2 A). Phosphatidylcholine, which is a major constituent of 
eukaryotic membranes, has a cylindrical shape (Figure 1-2 B), while another common bilayer 
constituent, phosphatidylethanolamine, –has a small head group that gives it inverted cone 
geometry (Figure 1-2 C)26.  The phospholipids with cylindrical geometry can pack tight together 
and tend to produce solid “gel-like” membranes (Figure 1-2 D), whereas conical shaped 
phospholipids tend to increase membrane curvature, which also appears to be important for 
insertion of membrane proteins26,40,42. Moreover, combinations and ratios of saturated to 
unsaturated fatty acid chains also determine lipid packing, membrane viscosity, as well as 
water permeability in the membrane26,40,43,44. GPLs with long saturated fatty acid chains tend 
to produce thicker, relatively rigid membranes (Figure 1-2 D). This is because the saturated 
fatty acid chains pack tightly together. On the other hand, the double bonds of the unsaturated 
fatty acids cause kinks which prevent tight packing of the membrane thereby making the 
membrane more fluid (Figure 1-2 E). The introduction of sterol lipids such a cholesterol also 
have “fluidizing” effects that produce relatively fluid membranes that also tend to be thicker 





Figure 1-2: Phospholipid composition determines membrane fluidity. Lysophospholipids generally have 
conical molecular geometry (A). Phospholipids with large head groups like phosphatidylcholine assume a 
cylindrical (B) shape, whereas the phospholipids with relatively small headgroups like phosphatidylethanolamine 
assume inverted conical molecular geometry (C). The fatty acyl chain saturation also contributes to the molecular 
geometry also determines membrane fluidity. Saturated phospholipids pack tightly together to produce “gel-like” 
membranes (D), whereas the kinks produced by the double bonds in unsaturated fatty acid chains pack less tightly 
to produce membranes of higher fluidity (E). Finally, introducing sterol lipids (symbolised by yellow shapes) such a 
cholesterol also have a “fluidizing” effect that also leads to membranes that tend to be thicker than non-sterol 
containing membranes (F). Adapted from Ernst et al.42 
1.2.3 How do we study membrane permeation by passive diffusion? 
There are different factors to consider when studying membrane permeability. The selection 
of models for this purpose largely depends on the membrane transport mechanism in 
question. The evolution of drug discovery towards HTS prompted the complimentary 
development of high-throughput permeability screening methods. The most popular of these 
include the use of Caco-2 monolayers and the PAMPA assay, both of which are briefly 
discussed below. These are contrasted with the use of liposomes that are not necessarily 
suitable for high-throughput screening but are still an important tool for studying membrane 
permeability in vitro.  
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1.2.3.1 Caco-2 monolayers 
Caco-2 monolayers are immortalized cell lines derived from human colon adenocarcinoma 
cells that are grown on Transwell® polycarbonate membranes to be used as a transport model 
system for the small intestinal epithelium45,46. As such, they are most often used to predict the 
likely rate of absorption of compounds in the intestine. These are popular because the assay 
can be performed in a high-throughput format, and also because the monolayers are a 
representation of biological membranes47–50. However, they are exclusively used as a 
mammalian membrane model. The lack of versatility, inability to distinguish between passive 
and active transport, as well as the high cost of maintaining the cell lines are some of the 
drawbacks of this method 4748–50.  
1.2.3.2 PAMPA assay 
The Parallel Artificial Membrane Permeability Assay (PAMPA)50–52 is more cost effective than 
the monolayer assays as it does not require maintenance of cell lines. However, as is the case 
with the Caco-2 monolayers, PAMPA assays usually model mammalian cell membranes 
exclusively. Furthermore, PAMPA assays are exclusively prepared from synthetic lipids and 
the preparation is such that the researcher cannot manipulate the phospholipid composition.  
1.2.3.3 Liposomes 
While the characteristics of the Caco-2 monolayer and PAMPA assays make them 
indispensable as screening tools, these methods are often not useful as investigational tools, 
especially when the aim is to understand in greater detail how a drug molecule permeates the 
membrane. For such studies, liposomes often offer the best alternative. Liposomes are  
microscopic spherical artificial vesicles created from natural phospholipids, with or without 
cholesterol53. Liposomes have traditionally been used to study biological membranes in 
general, and have several practical applications, the most notable of which is drug delivery 
studies. The environmental temperature, conditions of the lipid-water mixture as well as the 
molecular geometry of the lipids all determine the kind of colloidal particle produced (Figure 
1-3)54. Detergents and lysophospholipids which have conical shapes tend to produce normal 
micelles (Figure 1-3 A). Phospholipids of cylindrical molecular geometry such as 
phosphatidylcholine and phosphatidylserine usually promote formation of lamellar vesicles 
(Figure 1-3 B). These vesicles can have single or multilamellae, and the term “liposome” 
usually describes single lamellar vesicles. On the other hand, phosphatidylethanolamine and 




Figure 1-3: The molecular geometry of phospholipids determines the type of liposomal aggregate. 
Phospholipids aggregate spontaneously in aqueous conditions and the colloidal particles formed depend on the 
properties of the aqueous solution as well as the molecular geometry of the phospholipids used. Phospholipids of 
conical geometry form micelles (A), cylindrical phospholipids form lamellar vesicles (referred to as liposomes) (B) 
and inverted conical phospholipids form inverted micelles (C). 
Cell-sized liposomes that encapsulate biomolecules provide a versatile mimic of certain 
aspects of the cell membrane54,55. In addition to this, the lipid composition can be manipulated 
as required, so liposomes can adopt versatile physical characteristics30,56. Liposomes also 
have a low toxicity, and an ability to enclose a wide variety of molecules within its cavity53,57. 
These properties make liposomes attractive as an investigational tool for a large diversity of 
membrane and membrane permeability studies.  
Taken together, these show that despite recent technological advances to improve drug 
discovery turnover, no new classes of drugs have been identified in the recent years. This can 
Stellenbosch University https://scholar.sun.ac.za
12 
largely be attributed to a poor understanding of membrane permeability of drug-like molecules. 
Moreover, whilst guidelines like Ro5 have been useful in predicting – with reasonable 
accuracy, the probability of a drug molecule to be orally available, such guidelines cannot 
continue to substitute a fundamental understanding of drug permeability. This is particularly 
since a substantial amount of recently FDA approved drugs do not obey Ro5, whilst many of 
the Ro5 obeying molecule go into attrition. This shows that without a fundamental 
understanding of the molecular determinants of small molecule permeability we cannot hope 
to make any meaningful progress as far as it relates to drug discovery. Therefore, we use CoA 
focused drug development to illustrate how poor permeability continues to stunt progress in 
this field, and how we could benefit from a systematic investigation of small molecule 
permeability. We make a case for the pantothenamides, which are structural analogues of the 
CoA precursor pantetheine, as good candidates to help us understand the key structural 
features that confer permeability (or impermeability) of small molecules, and how insight 
gained from such an investigation can help us improve (without compromising potency 
towards the target) membrane permeability of potential drug molecules. 
1.3 Coenzyme A metabolism and CoA-focused drug discovery: a case study 
in the biological relevance of the membrane permeability of small 
molecules 
In the early days following its discovery, CoA (1, Figure 1-4) was viewed as an “acetate 
activator”, hence the name coenzyme A (the “A” referring to acetate)58. This coenzyme is 
required by a substantial amount of enzymes for catalytic activity. As such, it is implicated in 
a number of essential biological processes like energy metabolism, protein acetylation and 
fatty acid metabolism, to name a few59–62. CoA also acts by serving as the source of the 
phosphopantetheine modification that is found in most acyl- and peptidyl carrier proteins 
(Figure 1-4). Whether in such proteins or in CoA itself, the functionally relevant component is 
the terminal –SH on the phosphopantetheine moiety, as it forms thioesters with the –COOH 




Figure 1-4: The structure of coenzyme A (CoA), with its 4'-phosphopantetheine (P-PantSH) moiety 
highlighted. 
We have highlighted the potential benefits of investigating membrane permeation of drug 
molecules form the standpoint of maximising drug discovery output. However, such 
investigations can additionally lead to the discovery of novel targets for drug development. For 
instance, there are many so-called “orphan” transporters, so named because the molecules 
they transport are yet to be identified – which indicates the extent to which small molecule 
transport remains unexplored. To make a case for this, we use pantothenate to show that 
uptake mechanisms of essential molecules can be a viable target for drug development.  
Most organisms can synthesise CoA de novo from vitamin B5, which is also known as 
pantothenic acid (PanCOOH, 2)63 (Figure 1-5). In addition to this, some fungi, bacteria and 
plants can also synthesise PanCOOH de novo from β-alanine and α-ketoisovalerate63. Most 
organisms also have membrane transport proteins which enable uptake of this molecule from 
the external environment. Such transporters have been characterized in both prokaryotic and 
eukaryotic organisms64–69. Some functional divergence in these transporters has been 
established, especially in protozoans which suggests possibility for selective targeting of 
pantothenate uptake in  these organisms for drug discovery purposes65,70,71 . 
1.3.1 Pantothenate uptake mechanisms 
Some plants, fungi and bacteria (including Escherichia coli) can synthesise CoA de novo from 
PanCOOH72. However, gene knockout studies performed in E. coli show that it remains viable 
even after the genes encoding the PanCOOH biosynthetic enzymes were silenced. This 
served to show that de novo PanCOOH biosynthesis is not required for survival of the 
organism, and that it also has mechanisms for direct uptake of this molecule from the 
environment. The uptake is mediated by a membrane transport protein called pantothenate 
permease (PanF)68. It is a sodium-associated (symporter) transporter that is highly specific for 
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the vitamin (transport constant of 0.4 μM)73.  Homologues of this transport protein have also 
been identified in other bacteria such as Haemophilus influenza and Salmonella typhi74–76.  
Most mammals are incapable of synthesizing PanCOOH de novo and must assimilate it from 
their environment. Uptake of PanCOOH in these organisms is facilitated by SLC5A6, a 
sodium-dependent multivitamin transporter (SMVT)66,77–79. This transporter accepts 
PanCOOH, biotin and lipoate as substrates, hence its name. This symporter has a relatively 
low affinity towards PanCOOH with a Km ≈1.5–4.9 μM. A homologue of this transporter (FEN2) 
is also expressed in Saccharomyces cerevisiae64. However, the yeast transporter differs from 
the SMVT in that it transports PanCOOH in a proton gradient-dependent manner. 
Furthermore, its PanCOOH uptake is stimulated by glucose, which also happens to be an 
activator of the proton-ATPase64.  
Plasmodium falciparum, the causative agent of malaria, has an absolute requirement for 
PanCOOH80,81. The intra-erythrocytic stage of this parasite is easy to reproduce in vitro and 
for this reason is also the best studied. Since erythrocytes are metabolically inert these cells 
have no mechanisms for PanCOOH uptake. Upon infection, the parasite induces new 
permeability pathways (NPPs) in the erythrocyte membrane to facilitate PanCOOH uptake into 
the erythrocyte82. However, the NPPs are not only specific for PanCOOH, but have the ability 
to take up various compounds and solutes83. The uptake of PanCOOH by the parasites itself 
is very rapid. PanCOOH is presumed to be present in the parasitophorous vacuole. This 
vacuole forms as soon as the parasites invade the erythrocyte and occurs via an endocytosis-
like mechanism. During this process, the parasite remains enclosed. It is believed that 
PanCOOH diffuses over the vacuole membrane via low selectivity channels81. P. falciparum  
expresses a pantothenate transporter as is the case for its mammalian host and bacteria65,70. 
Therefore, once the PanCOOH is present in the parasitophorous vacuole, it can then be taken 
up by the parasite via its pantothenate transporter. However, this transporter is divergent from 
both the bacterial and mammalian transporters in regards to both its sequence and its 
characteristics. It is a symporter that requires a proton gradient rather than a sodium gradient, 
and it has lower affinity for PanCOOH relative to the mammalian transporter, with a Km of 23 
mM80.  
1.3.2 Efflux pumps reduce efficacy of PanCOOH analogues in Gram-negative 
bacteria 
The chemical synthesis of libraries of PanCOOH analogues to be tested as potential 
antibacterial agents also led to discoveries regarding other transporter-based processes81. For 
example, specific pantothenamides (PanAms, a class of PanCOOH analogues in which the 
carboxyl is replaced with N-substituted amides) such as N-pentylpantothenamide (N5-Pan, 6) 
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and N-heptylpantothenamide (N7-Pan, 7), respectively (Figure 1-5) have been shown to be 
metabolically activated through the CoA biosynthetic pathway to ethyldethia-CoA and 
butyldethia-CoA84,85. These elicit bacteriostatic activity by producing crypto-ACPs which inhibit 
fatty acid biosynthesis86,87.  N5-Pan has moderate potency towards E. coli and S. aureus, but 
N7-Pan is exclusively potent towards S. aureus. Importantly, the low efficacy of N7-Pan 
towards E. coli was found to be due to rapid efflux by TolC proteins found on the outer 
membrane of Gram-negative bacteria.  
 
Figure 1-5: Chemical structures of Pantothenate analogues with promising antibacterial activity. PanCOOH 
is made up of pantoyl and β-alanine moieties (2). The β-alanine moiety is modified with an N-substituted amide (8), 
or is replaced with either a γ-aminobutyric acid or glycine to produce α- and HoPanAms, respectively. The most 
potent PanAms to date include N5-Pan, N7-Pan and CJ-15,801 (11, 12 and 13, respectively), but 12 and 13 the 
latter loose potency due to efflux by TolC pumps. 
1.3.3 Targeting PanCOOH uptake mechanisms for antimicrobial drug discovery 
Since PanCOOH can be synthesized de novo by bacteria, it is not a viable strategy to target 
its uptake for antibacterial drug development in most cases. However, the lack of PanCOOH 
transport mechanism in erythrocytes, together with the low sequence and functional homology 
of the parasite and host transporters suggest possible selective targeting of the uptake of 
PanCOOH by the malaria parasite P. falciparum for antimalarial drug development. But, the 
PanCOOH analogues tested on blood stage parasite that do show antiplasmodial activity to 
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date, do not seem to act by interfering with PanCOOH uptake. These include pantothenol 
(PantOH, the reduced version of PanCOOH) (9), CJ-15,801 (a fungal natural product that only 
differs from the vitamin in having a single bond exchanged for a double bond) (8), and the 
PanAms (Figure 1-5)88. In the case of the latter, a range of analogues were tested in which 
other features of the molecule were changed as well. Specifically, the β-alanine moiety of 
PanCOOH was replaced with either a glycine or γ-aminobutyric acid, giving rise to three sets 
of PanAms:  the n-PanAms (3), with the usual β-alanine moiety, the α-PanAms (5), which are 
substituted pantoylglycyl amides and the HoPanAms (4), which are amides of pantoyl γ-
aminobutyric acid89. Investigation of mode action of these molecules showed that the α-
PanAms indeed compete with PanCOOH for transporter-mediated uptake but do not show 
potency towards the parasite. On the other hand, the n-PanAms and HoPanAms that did elicit 
some antiplasmodial activity in vitro, were shown to permeate these organisms by passive 
diffusion90. These findings were the first to provide evidence that a) small changes in the 
structures of PanCOOH analogues have a large impact on their recognition by transporters, 
and b) that these changes may also affect the membrane permeability of the compounds. 
This, in turn, suggested that the PanAms (and other PanCOOH analogues) can be used to 
study membrane permeability in the context of drug discovery. 
1.3.4 Diverse modes of CoA formation in vivo provide evidence of the importance of 
membrane permeability to CoA biology  
1.3.4.1 Canonical CoA biosynthesis pathway  
In organisms that do not make their own PanCOOH, CoA (1) is synthesised de novo from 
PanCOOH that is obtained from the diet or the external environment (Figure 1-6 A). The 
biosynthesis occurs through a five step pathway mediated by the enzymes pantothenate 
kinase (PanK)91,92, phosphopantothenoylcysteine synthetase (PPCS)93, phosphopanto-
thenoylcysteine decarboxylase (PPCDC)94, phosphopantetheine adenylyltransferase 
(PPAT)95 and dephospho-coenzyme A kinase (DPCK)94.  
PanK catalyzes the ATP-dependent phosphorylation of PanCOOH (2) to form 4'-
phosphopantothenate (P-Pan, 10), the first step of the pathway. There are at least three known 
PanK types that can be distinguished based on sequence, structure, active site architecture 
and specificity towards PanCOOH96.  A type I PanK (PanKI) was first isolated from E. coli, and 
has relaxed substrate specificity and can accept pantetheine (PantSH) as an alternative 
substrate. Consequently, it is involved in both de novo biosynthesis of CoA, and in the CoA 
salvage pathway. PanKI is also subject to feedback inhibition by CoA and to a lesser extent 
by the CoA thioesters which competitively inhibit ATP binding97–99. Type II PanK (PanKII) 




Figure 1-6: Various routes for formation of CoA. CoA (1) is biosynthesised de novo from PanCOOH (2) that is 
taken up from the external environment by dedicated transporters (in the case of organisms that cannot synthesise 
their own PanCOOH) (A). This process in involves the five enzymes: PanK, PPCS, PPCDC, PPAT and DPCK, the 
last two of which are fused in a bifunctional enzyme complex in most mammals, called CoA synthase (CoASy).  In 
addition, PantSH (12) can serve as also serve as substrate for the formation of CoA through a truncated form of 
the pathway called the CoA salvage pathway (B). This pathway becomes possible in cases where PantSH is taken 
up (most likely through passive diffusion, i.e. bypassing the need for membrane transporters) and subsequently 
acted on by PanK, PPAT and DPCK. Finally, when P-PantSH (6) is formed by rapid degradation of exogenous 
CoA it can also serve as a precursor for the formation of CoA through the action of only PPAT and DPCK (C). 
Importantly, P-PantSH has been shown to be taken up through passive diffusion by some cells, indicating that this 
pathway is not dependent on any transporters either. 
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Unlike the bacterial PanKs which are encoded by a single gene, the mammalian PanKIIs 
exhibit heterogeneity with three genes encoding four distinct isoforms: PANK1α, PANK1β, 
PANK2 and PANK3. Like PanKIs, PanKII enzymes also have relaxed substrate specificity and 
are subject to feedback inhibition by CoA and its thioesters with the latter being more potent 
feedback regulators than free CoA100,101. There is an atypical PanKII found in some bacteria 
such as Staphylococcus aureus.  
This protein is homologous to the eukaryotic PanKII and, although it also accepts PantSH as 
an alternative substrate, the  turnover rate is so slow that in practice it actually acts as a 
competitive inhibitor of the enzyme74,102. This could possible form part of an alternative 
regulation mechanism, as a major distinguishing factor of this enzyme is that it does not 
experienced feedback inhibition by CoA and its thioesters101. The type III PanKs (PanKIIIs) are 
the most recently discovered of the PanK types and is exemplified by the enzyme from 
Helicobacter pylori99 Like PanKI enzymes, this type is predominantly found in prokaryotic 
organisms—in fact, more bacterial species have PanKIII enzymes than PanKIs.  PanKIIIs 
exclusively accept PanCOOH as a substrate (i.e. it is not able to partake in the CoA salvage 
pathway), and is also not subject to feedback inhibition by any known metabolite96,99. 
The second step is the Mg²⁺-dependent formation of 4'-phosphopantothenoylcysteine (P-
PanCys, 11) from 4'-phosphopantothenate, ATP (CTP in the case of bacteria) and L-cysteine 
as catalyzed by PPCS. The third step of the pathway involves PPCDC, which catalyzes the 
decarboxylation of the cysteine moiety of P-PanCys to form 4'-phosphopantetheine (P-
PantSH, 13). The two enzymes are fused as part of a bifunctional enzyme complex called 
CoaBC in most bacteria93,103. However, there are some bacterial species—mainly the 
streptococci and enterococci—in which the two enzymes are expressed as separate enzymes. 
Some bacterial species also exhibit heterogeneity characterized by the presence of both the 
bifunctional complex, as well as monofunctional enzymes104. PPCS and PPCDC exist as 
separate monofunctional enzymes in most eukaryotic organisms105. 
The penultimate step of the pathway is the reversible Mg²⁺-dependent adenylylation of 4'-
phosphopantetheine to form dephospho-CoA (dePCoA, 14) and pyrophosphate (PPi) 
catalyzed by PPAT95. And finally, DPCK catalyzes the selective MgATP-dependent 
phosphorylation of the 3'-hydroxyl of the ribose moiety of dePCoA to form the final product of 
the biosynthetic pathway, CoA (Figure 1-6). In mammals, PPAT and DPCK exist as a 
bifunctional enzyme complex called CoA synthase (CoASy)106, but are separate 
monofunctional enzymes in most bacteria107. In addition to CoASy, mammalian cells express 
an additional monofunctional DPCK. This heterogeneity may be important for homeostasis of 
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organellar CoA pools, since current evidence suggests that the monofunctional enzyme 
localizes to the cytoplasm, while CoASy localises to the mitochondria108. 
The biosynthesis of CoA from PanCOOH by this “canonical pathway” has long been thought 
to be only way in which cells can obtain this cofactor. As such, the phosphorylation of 
PanCOOH by PanK has long been considered a key regulatory step, and that the PanK 
reaction commits the cell to CoA biosynthesis86. However, as outlined below, recent findings 
have suggested that the reality is more complex, and that the membrane permeability of the 
CoA biosynthetic intermediates is an important component of this complexity.  
1.3.4.2 CoA salvage pathway 
Pantetheine (PantSH, 12) is the amide formed from cysteamine and PanCOOH (Figure 1-6 
B). This molecule may serve as an alternative precursor for the formation of CoA since its 
phosphorylation by PanK produces 4'-phosphopantetheine (P-PantSH, 13)—the third 
intermediate of CoA biosynthesis—directly. This means that, apart from PanK, only the last 
two enzymes of the pathway are required to produce CoA. This truncated form of the pathway 
is known as the CoA salvage pathway.  
PantSH is usually derived from pantethine (disulfide of PantSH) which is often used as a 
dietary supplement109,110. It is also likely produced by dephosphorylation of P-PantSH by 
selective phosphatases that control the levels of certain metabolites111. Importantly, nutrient 
complementation studies in Pseudomonas aeruginosa mutant strains that are auxotrophic for 
pantothenate, and in which the panF and coaBC genes (the latter encoding the bifunctional 
PPCS/PPCDC protein in this organism) have been down regulated, show that PantSH can 
support its growth when it is complemented with a PanK enzyme capable of phosphorylating 
PantSH. This suggests membrane permeation of this molecule in a PanF-independent 
manner (Figure 1-6 B)112. Moreover, it also provided the first clear basis for the apparent 
membrane permeability of certain PanAms, as this class of compounds is clearly closely 
related structurally to PantSH.  
1.3.4.3 Alternative CoA biosynthetic routes 
A long-standing interest in CoA biosynthesis is related to the discovery of pantothenate kinase-
associated neurodegeneration (PKAN), one of a group of neurodegenerative diseases 
collectively called neurodegeneration by brain iron accumulation (NBIA).  A hallmark of PKAN 
is a mutation in the gene that encodes the mitochondrial human PanK isoform. This mutation 
renders the enzyme catalytically inactive, leading to CoA depleted phenotypes113. Results 
from a nutrient complementation study with Drosophila melanogaster PKAN models show that 
exogenous CoA can rescue the intracellular CoA depletion and so alleviate some of the 
symptoms of the disease114,115 Further investigation revealed that the exogenous CoA is 
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degraded into P-PantSH by ectonucleo-pyrophosphatases (ENPPs), that P-PantSH is 
biologically stable and that it can enter certain cells by passive diffusion115,116. As it is an 
advanced CoA biosynthesis metabolite, once inside the cell it can be transformed into CoA 
only by the action of PPAT and DPCK, as a precursor for CoA biosynthesis through an 
alternative route that bypasses PanK (Figure 1-6 C).  
This finding was especially surprising as it indicated that a phosphorylated metabolite, P-
PantSH, was able to cross cell membranes—contrary to the standard permeability paradigm 
that charged molecules are membrane impermeable. However, as outlined in more detail 
below, the findings also indicated that the permeability of P-PantSH permeability was not 
general. Elucidating the basis for its ability to cross membranes, as well as the characteristics 
of the kind of membranes that allows this, is therefore clearly an important goal to be achieved,  
1.3.5 CoA homeostasis and its implications for drug development 
1.3.5.1 There are distinct subcellular CoA pools in mammals 
Eukaryotic cells have distinct cytosolic, mitochondrial, peroxisomal and intrareticular CoA 
pools86,108. However, the mechanisms by which these pools are established or regulated 
remains largely unknown. The heterogeneity and specific localization of PanK isoforms in 
mammals suggest that they might play an important role in this regard, as knockout studies 
show that the loss of one PanK isoform is not always compensated for by another. This may 
be attributed to the differences in their N-terminal domains that are presumed to direct their 
subcellular localization117,118.  
Immunocytochemistry and co-localization studies show that PANK1α localizes to the nucleus, 
that PANK1β is associated with vesicles, PANK3 localizes to the cytosol, and finally PANK2 
is exported from the nucleus to the mitochondrion in a cell-cycle dependent manner118–121. 
There is further evidence to suggest specific localisation of PANK2 to the inner mitochondrial 
space. It is hypothesized that this organellar localisation occurs to allow export of 4'-
phosphopantothenate—the product of the PanK-catalyzed reaction—into the cytoplasm 
where the rest of the biosynthetic enzymes are presumed localized. This hypothesis was 
formulated on the basis that CoA biosynthesis does not take place in the subcellular 
compartments to which the individual PanK isoforms localize. It is further postulated that the 
subcellular localisation allow PanKs to act as sensors for CoA homeostasis in the respective 
organelles118. This in turn is based on the dogmatic view of PanK experiencing feedback 
inhibition by CoA and its thioesters which in turn translates to its involvement in the 
maintenance of homeostatic levels of CoA through their production of 4'-
phosphopantothenate. Such a perspective requires not only the transport of 4'-
phosphopantothenate, but also that CoA is exported from the cytoplasm into the specific 
Stellenbosch University https://scholar.sun.ac.za
21 
organelles. Since charged molecules generally do not cross membranes, it is presumed that 
CoA is membrane impermeable108. It consequently follows that free CoA must be transported 
between subcellular compartments by dedicated transporters located on the membranes of 
the different organelles. While transporters which seem to have such activity have been 
identified, no evidence of their direct transport of CoA has been obtained as yet. 
The current hypothesis may be flawed for the following additional reasons: it overlooks 
experimental evidence that suggests the localisation of CoASy to the mitochondrion122, and it 
also disregards the proposed localisation of PANK3 to the cytoplasm118. Taken together, this 
highlights the importance for an improved understanding of the membrane permeability of CoA 
and its biosynthetic intermediates, and the various factors that may impact on it.  
1.3.5.2 Defects in mammalian PANK 2 and CoASY are associated with mitochondrial 
dysfunction 
The highest concentration of CoA is found in the mitochondrion and the peroxisome, which 
suggests that regulation of CoA levels in these organelles is independent of that of the 
cytoplasmic pool123–125. The organellar CoA pools appear to be tightly regulated especially in 
the case of the mitochondria where defects in CoA metabolism is linked to pathological 
conditions such as PKAN114,115,120. Another variation of the neurodegenerative condition is 
CoASy associated neurodegeneration (CoPAN) which is associated with defects in CoASy 
activity109,126. 
The identification of transporters with apparent activity for exchanging  CoA and dePCoA for 
other nucleotides in the mitochondrion and peroxisome provides further evidence to support 
the suggestion that CoA regulation in these organelles occurs independently123–125. This is 
further illustrated by findings from knockout studies on the gene encoding SLC25A16, an inner 
mitochondrial transporter associated with CoA transport. Silencing of this gene resulted in the 
reversal of the CoA concentration between the mitochondrion and the cytosol. However, direct 
evidence of the transport of CoA or a CoA biosynthetic intermediate by this transporter still 
needs to be obtained.  
1.3.5.3 P-PantSH may play a role in the regulation of subcellular CoA pools in mammals 
As alluded to previously, there is evidence pointing towards an alternative route for obtaining 
CoA in eukaryotes (Figure 1-6).  Disruption of de novo CoA biosynthesis by silencing genes 
that encode selected CoA biosynthetic enzymes led to low intracellular CoA levels and 
decreased protein acetylation in D. melanogaster S2 cell knockout models. However, the 
protein acetylation could be recovered by adding CoA to the culture medium. Therefore, the 
findings of this study suggest that exogenous CoA could supply intracellular CoA pools115. 
Further investigation went on to reveal that exogenous CoA is degraded into P-PantSH and 
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3',5’-ADP by ENPPs115. P-PantSH is not susceptible to degradation by pantetheinases and is 
therefore stable in culture media as well as in circulation in vivo115,127. Membrane permeability 
screens of this molecule using the PAMPA assay also suggested that this molecule can enter 
cells by passive diffusion115.  
 
Figure 1-7: P-PantSH may play a role in homeostasis of subcellular CoA pools in mammalian cells. The 
apparent heterogeneity of CoA biosynthetic enzymes is linked to maintenance of subcellular CoA pools in these 
organisms. For instance: PanK 1 and 3, PPCS as well as PPCDC localise to the cytosol implying biosynthesis of 
P-PantSH in the cytosol. This molecule should then be exported to the mitochondrion where CoASy is localised for 
the final steps of CoA biosynthesis. Since transporters with affinity towards dePCoA and CoA have been identified 
on this organelle, it follows that P-PantSH may enter the organelle by counter exchange with these molecules. 
Furthermore, localisation of PanK 2 to the mitochondrion implies CoA biosynthesis by salvage with further suggests 
existence of uptake mechanisms of PantSH in this organelle. On the other hand, a transporter with affinity towards 
dePCoA and CoA has been identified on the peroxisome as well. This transporter may also have affinity for P-
PantSH, since in addition to its unaided membrane permeation, this molecule is synthesised in the cytosol.  Taken 
together, these suggest possibility of involvement of P-PantSH in homeostatic regulation of subcellular CoA pools.  
 
Since subcellular transporters are believed to transport either CoA or one of its intermediate 
for maintenance of the various organellar CoA pools, it is tempting to speculate that this may 
occur by means of P-PantSH, based on its demonstrated biological stability and membrane 
Stellenbosch University https://scholar.sun.ac.za
23 
permeability (Figure 1-7). This would especially be the case in mitochondria, as this is where 
current evidence indicates that CoASy localizes, and as such P-PantSH would be able to 
serve as the precursor for CoA formation in the mitochondria through the action of CoASy. 
1.3.5.4 P-PantSH is irreversibly removed from E. coli for homeostatic regulation of CoA and 
ACP 
In an important foundational study, CoA intermediates were quantified in an effort to try and 
understand the flux through the CoA biosynthetic pathway in E. coli. PanCOOH and P-PantSH 
were found to be the most abundant intermediates in the cell128. The same study went on to 
suggest that P-PantSH is irreversibly removed from the cell for homeostatic regulation of CoA 
and the biosynthesis of active acyl carrier proteins (ACPs) (Figure 1-8)128. ACP is required for 
fatty acid biosynthesis in bacteria. It exists as an inactive apo form that is activated to the holo 
form by covalent attachment of the P-PantSH moiety of CoA in a post-translational 
modification of the protein. Intracellular holo-ACP is recycled to its apo form and P-PantSH 
through hydrolysis mediated by the enzyme ACP hydrolase (AcpH)129.  As such, free P-
PantSH in the E. coli cell can be attributed to both CoA and ACP recycling, As well as the slow 
reaction rate of PPAT (the enzyme that transforms P-PantSH into dePCoA), relative to the 
other enzymes in the pathway128,129.  
 
Figure 1-8: P-PantSH is proposed to play a role in the homeostatic regulation of CoA and ACP levels in 
E.coli. CoA is biosynthesised through the canonical pathway from PanCOOH actively taken up by PanF. The 
produced CoA activates ACP from the apo- to the holo-ACP form in a process mediated by ACP synthesis. ACP 
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and CoA are recycled by hydrolysis to yield P-PantSH in a process mediated by ACP and CoA hydrolase 
respectively. P-PantSH is the irreversibly removed from the cell to maintain homeostatic levels of both CoA and 
ACP. 
1.3.5.5 CoA related interplay between microbiota and the eukaryotic host may be mediated 
by P-PantSH 
The apparent irreversible removal of P-PantSH from E. coli suggest that this organism, 
together with other members of the gut microbiota, can provide excess P-PantSH to the 
eukaryotic host108.  Studies on D. melanogaster models in which PanK was inactivated to 
prevent de novo biosynthesis of CoA, show that these organisms could still survive the early 
embryonal and larval stages because basal levels of CoA persisted108. It is probable that this 
was due to CoA being formed by the conversion of P-PantSH obtained from the D. 
melanogaster gut flora.  
This postulation is further reinforced by findings from a study on murine models which were 
fed a PanCOOH depleted diet114. Despite this depletion, these animals did not experience any 
symptoms unless antibiotics were also administered with the diet. It is possible that when the 
animals were deprived of PanCOOH, the required CoA biosynthesis occurred through P-
PantSH obtained from the microbiota108,115 . 
This interplay of P-PantSH between host and bacterium can also apply in the reverse direction 
when organisms such as Treponema pallidum are considered (Figure 1-9). T. pallidum is the 
causative agent of syphilis108. Comparative genomic data suggests that it has an unusual CoA 
biosynthetic machinery ensemble consisting of a PanKIII, PPAT and DPCK, but no PPCS or 
PPCDC enzymes115. These organisms cannot use PantSH as a CoA precursor for the CoA 
salvage pathway since PanKIII exclusively accepts PanCOOH as a substrate. Moreover, the 
organism does not have PPCS and PPCDC enzymes, which in turn suggests that the 
phosphorylation of PanCOOH would be futile, as the produced 4′-phosphopantothenate 
cannot be biotransformed any further. Early nutrient complementation studies performed on 
the Treponema spp. also suggested a preference for P-PantSH over PanCOOH and PantSH 
as a starting material for CoA biosynthesis115. This suggests that these organisms are 
obtaining the P-PantSH required for CoA biosynthesis from the circulation of its eukaryotic 
host (Figure 1-9). Comparative genomic data suggests that other intracellular parasitic 
organisms such as Mycoplasma spp. may follow a similar approach for CoA biosynthesis108 
Taken together, these point towards P-PantSH as a nexus metabolite of CoA biosynthesis 
and degradation. Moreover, uptake mechanisms in organisms like T. pallidum may be a viable 





Figure 1-9: P-PantSH abundance provides an alternative route for CoA biosynthesis.  P-PantSH is biologically stable and can therefore stay in host circulation for prolonged 
periods. This in turn implies that P-PantSH can serve as a CoA precursor for organisms with unusual biosynthetic machinery such as T. pallidum which demonstrates preference 







1.3.6 Problem statement 
A vast amount of knowledge has been acquired in the past two decades regarding 
pantothenate analogues and their potential use as therapeutics. It is known that the uptake of 
these analogues differs between organisms, however, the exact mechanism of uptake is not 
well studied between analogues and thus unclear. This is compounded by the complexity of 
CoA homeostasis and the poor understanding thereof. While numerous PanCOOH 
transporters have been characterized, the uptake mechanisms of this molecule or how it is 
regulated is still vague. This is best illustrated by the intra-erythrocytic stage of P. falciparum, 
where there is an interplay between host and pathogen cells to ensure PanCOOH uptake by 
the parasite. The permeability of PantSH and PanAms has also been speculated on, but there 
is still no experimental data that can definitively confirm the mechanism by which these 
molecules enter the cell.  
Another factor that contributes to the lack of knowledge of pantothenate analogue uptake is 
the poor understanding of CoA homeostasis between a eukaryotic host and members of its 
microbiome. This process may involve exchange of CoA intermediates between the host and 
bacteria. Subcellular CoA pools are maintained by tight regulation of the transmembrane 
transport of CoA and/or its intermediates in eukaryotic cells. Existing experimental evidence 
points towards P-PantSH as the key intermediate in this process. There is also evidence to 
suggest the role of this molecule in homeostatic regulation of CoA and ACP in E. coli cells. 
This together with the apparent biological stability of P-PantSH, suggests an interplay between 
the eukaryotic host and its microbiome in regards to CoA metabolism.  
Existing experimental evidence suggests that some pantothenate analogues, like PantSH and 
PantOH, may permeate cell membranes by methods independent of protein transporters. This 
is presumed to occur by passive diffusion, based on the observation that P-PantSH can rescue 
CoA-depleted phenotypes in Drosophila S2 cells in a non-saturable manner115. Therefore, we 
would like to investigate the molecular determinants of membrane permeability of these 
molecules by addressing the following questions: Is it the pantoyl, cysteamine or phosphate 
moiety that confers permeability, or does the membrane composition have a greater role to 
play in this regard? Insight gained from such a study will not only help us understand how 
these molecules cross membranes but will also inform strategies for mitigating poor 
permeability of certain PanAms, some of which are potent inhibitors of their targets in vitro but 
fail to elicit antibacterial activity. 
The study also seeks to characterize the SLC25A16, a mitochondrial carrier implicated in the 
regulation of CoA levels in the mitochondria. Understanding the mechanism by which this 
transporter works will help us understand the link between mitochondrial CoA dysfunction and 
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pathological states like PKAN. We propose that P-PantSH may be a substrate for this carrier 
protein, and experimental demonstration of this may provide direct evidence linking this 
molecule to homeostatic regulation of subcellular CoA pools in is. Insight gained from 
characterizing this mitochondrial solute carrier may aid in identifying similar carriers which may 
be vulnerable targets for drug development in pathogenic organisms. 
Therefore, the following study aims were set out: 
1. Aim 1: To design and validate a liposomal fluorescence-based assay for measuring 
membrane permeability of CoA-related small molecules.  
The studies towards this aim is described in chapter 2 of this dissertation. 
2. Aim 2: To investigate the molecular determinants which confer membrane permeability 
of pantothenate analogues.  
This was achieved by performing membrane permeability measurements and 
membrane interaction studies of P-PantSH and other pantothenate analogues, as 
described in chapter 3.  
3. Aim 3: To characterize the mitochondrial solute carrier SLC25A16 associated with 
regulation of CoA levels in the mitochondrion. 
This work is described in chapter 4. 
The dissertation concludes with a short chapter summarizing the findings of the study, and a 
description of future work that would contribute to the results already achieved, with all the 






2 Development and validation of a discontinuous assay 
for measuring membrane permeability of P-PantSH and 
other CoA-related small molecules 
2.1 Introduction 
The current study seeks to investigate the membrane permeability of P-PantSH in order to 
find out if this molecule is unique in its ability to cross membranes unaided, if the permeability 
extends to different kinds of membranes, as well as to determine the membrane constituents 
that enable permeation by passive diffusion. This is in an effort to understand CoA 
homeostasis especially as it pertains to the interplay of CoA intermediates between 
eukaryotes and their microbiome. 
Membrane permeability of P-PantSH by passive diffusion has been inferred by findings from 
a nutrient complementation study of Drosophila melanogaster S2 cells as well as from results 
of a PAMPA assay115. It is important to highlight that the PAMPA assay does not distinguish 
between passive and membrane transporter mediated membrane translocation, and that it is 
an exclusively mammalian-based membrane model51,52. In contrast, the current study seeks 
to compare permeability of molecules between different membrane systems, including a 
bacterial model, and do so in such a manner that distinguishes passive diffusion from active 
transport. The PAMPA assay does not have the versatility required to achieve these objectives 
and we therefore elected to use a liposome-based assay for these studies. Liposomes do 
possess the versatility needed for this study as these particles can be functionalized as 
required by the investigator. It is therefore possible to prepare liposomes with lipid 
compositions that mimic either eukaryotic or bacterial membranes56,130–133. The liposomes can 
also be prepared with solutes loaded in the intraliposomal cavity, a feature that is useful for 
performing permeability measurements.  
Besides selecting a suitable membrane model, another important aspect to consider is the 
method used to perform permeability measurements. There are numerous published methods 
for measuring membrane permeability, many of which are based on radioactivity or 
fluorescence emission32,134–138. Whilst these methods have all generated useful data, a major 
drawback is that in most cases the measurements in transport exchange experiments are only 
directly made for one of the compounds being investigated, while transport of the other is 
being inferred. For instance, a study that characterizes a symport membrane transporter 
measured radioactivity exchange to determine the transporter kinetics of two target molecules 
transported in opposite directions of the membrane123. The radiolabeled version of one 
molecule was placed in the intraliposomal cavity, and the other in the external environment. 
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The change in radioactivity over time was subsequently monitored in the external environment. 
While this experiment can show the movement of the radiolabeled compound out of the 
liposome, the exchange with the unlabeled compound is inferred, as its transport into the 
liposome cannot be determined.  
Nevertheless, there are some assays that directly monitor the membrane translocation of a 
molecule of interest. One such assay was described by Eyer et al139.  It monitors the change 
in fluorescence of 8-hydroxypyrene-1, 3, 6-trisulfonate trisodium salt (pyranine), a pH sensitive 
dye to determine membrane permeability of the molecule of interest. Pyranine has high 
fluorescence emission at pH levels higher than 5.9 and is quenched at pH levels below this 
value. Pyranine-loaded liposomes were prepared according to the desired phospholipid 
composition. The pH of the extraliposomal environment was kept at pH 5.9 using the 
membrane-impermeable zwitterion 2-ethanesulfonic acid (MES). The intraliposomal cavity 
where pyranine was located was not buffered. This means the pH of the intraliposomal cavity 
was subject to pH fluctuations by dissociation of permeating molecules.  
 
Figure 2-1: Principle of the HTPS (pyranine)-based liposomal assay for measuring membrane permeability. 
The extraliposomal (outer) compartment is buffered (MES/NaCl, pH 5.9), whereas the liposomal lumen (inner) is 
unbuffered (A). After the addition of a weak base (B/BH+), permeation results in a net proton (H+) release at the 
outer membrane surface and a net proton capture at the inner surface, according to the Henderson–Hasselbalch 
equation, to reach equilibrium. This results in fluorescence changes of a pH-sensitive fluorescent dye (indicated by 
“pH ↑”) in the liposomal lumen or at the inner membrane surface while the proton at the outer membrane surface 
is neutralized by the buffer system (indicated by “pH →”). This is such that the membrane permeability of the 
molecule of interest can be determined by change in fluorescence over time. Adapted from Eyer et al. 139.  
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The drug molecules used in the assay have weak acid/based-like properties and could cause 
pH fluctuations in the liposomal cavity. This in turn, resulted in changes in pyranine 
fluorescence emission. The permeability of these drug molecules could hence be determined 
by changes in fluorescence intensity as a function of time (Figure 2-1).  
This is a good example of a liposome-based assay used to measure the permeability of small 
drug molecules. The value of this method lies in the principle that the assay measures changes 
in the liposomal environment due to exposure to the molecule of interest, and uses these 
changes to give measurable output about the permeability of the molecule. The assay uses 
an inexpensive, non-toxic fluorophore that is easy to dispose with the added advantage that 
the measurements are continuous with the potential for high-throughput method development.  
However, the assay does have some drawbacks. The use of pyranine suggests that only 
molecules that have weak acid/base properties can be profiled using this assay. The assay 
was also designed without a positive or negative control as a point of reference. This makes 
it difficult to distinguish true outcomes from false positives. In turn, this suggests a probability 
of observed outcomes not translating to an actual biological event. 
In this study we were particularly interested in studying the transport of CoA and its 
biosynthetic intermediates PantSH and P-PantSH, all of which are thiolated molecules. 
Therefore, we set out to devise a liposome-based membrane permeability assay specific to 
these molecules but with the versatility to measure membrane permeation by passive or 
protein-mediated modes on in vitro membrane models. The result was a fluorescence-based 
assay that uses a fluorophore that is complimentary to the properties of P-PantSH and other 
CoA intermediates.  The assay is set up in such a manner that it is amenable and can be used 
to measure permeability of molecules with structural diversity. 
2.2 Results and Discussion 
As previously stated, the main aim of this part of the study was to perform membrane 
permeability studies on P-PantSH and other CoA-related compounds that have structural 
similarity to P-PantSH. Liposomes were selected as an in vitro membrane model for 
investigating the membrane permeability of these molecules. Liposomes can exist in different 
forms like micelles, which exclude all hydrophilic molecules including water, and multilamellar 




Figure 2-2: Different types of liposomal vesicles can form. Examples of vesicles that can spontaneously form 
include single lamellar (unilamellar) (A), multilamellar (B) or multivesicular (C) liposomal vesicles. 
It is important that the liposomes be single lamellar vesicles of uniform size when investigating 
membrane permeability by passive diffusion39,40,44. Furthermore, the membrane permeability 
assay described in the current study requires that solutes be encapsulated in the 
intraliposomal cavity thereby making intraliposomal encapsulation efficiency an important 
factor to consider as well. The assay described by Eyer et al.139 involved preparation of 
pyranine-loaded liposomes. These were single lamellar vesicles with a molecule loaded in the 
intraliposomal cavity as is required for the current study. Furthermore, since pyranine is a 
fluorescent molecule, the formation of the vesicle could be confirmed by confocal microscopy. 
The pyranine loaded liposomes could thereby serve as a useful tool for evaluating liposome 
preparation as demonstrated below. 
2.2.1 Evaluation of liposome purification 
The pyranine-loaded liposomes were prepared by hydration of a lipid film with a solution 
containing pyranine, followed by extrusion to promote formation of unilamellar vesicles. The 
excess pyranine was removed by size exclusion chromatography on a Sephadex G50 column 
prepared in house. This was done to ensure that only intraliposomal pyranine was present in 
the preparation. The pyranine-loaded liposomes (without the excess pyranine) were then 
harvested by elution with gravitational force and collected in 500 μL fractions from the 
Sephadex-G50 column. Fractions containing a green opaque suspension were then collected 
and evaluated by confocal microscopy to confirm the presence of the pyranine-loaded 
liposomes. The collected fractions had relatively high background fluorescence with no 
definite liposomal particles (Figure 2-3). This is with the exception of Figure 2-3 B which had 




Figure 2-3: Liposomes prepared by 11 extrusion passages and purified with Sephadex-G50 column 
chromatography. “Pure” liposomal preparations were collected in 500 μL fractions indicated in panels A-D.  
Fraction B contained some particles presumed to be pyranine-loaded liposomes, however the background 
fluorescence signal was relatively high for all four fractions. This indicates the presence of extraliposomal pyranine. 
Since the background fluorescence signal was high, indicating an abundance of 
extraliposomal pyranine, all fractions were discarded. The liposomal preparation was 
attempted again, but the volume of fractions collected was increased to 1 mL for each fraction. 
Evaluation of two of these fractions showed more promising results than the previous 
preparation. Spherical particles that emit green fluorescence were observed. Furthermore, 
these had relatively low background signal which indicates successful removal of excess 
pyranine from the liposomal preparation (Figure 2-4).  
 
Figure 2-4: Liposomal preparation harvested by collecting 1 mL fractions the Sephadex-G50 column. The 
first two fractions collected are represented by the images in Panel A and B, respectively. Both images show 
spherical particles presumed to be pyranine-loaded liposomes. The relatively low background fluorescence signal 
suggests absence of extraliposomal pyranine. 
2.2.2 Comparison of extrusion and sonication  
Though the liposomal preparation and purification was successful as indicated by Figure 2-4 
the number of liposomes formed was relatively low and the fluorescence signal emitted by 
these liposomes was not strong. Consequently, the next objective was to investigate 
sonication as a technique to prepare single lamellar pyranine-loaded liposomes. This was 




Liposomes were once again prepared as described above, except that the lipid suspension 
was subjected to 5 minutes of sonication in an sonication bath (rather than to extrusion 
passages) to promote formation of single lamellar vesicles. The excess pyranine was removed 
by size exclusion chromatography and the liposomes were harvested by collecting 1 mL 
fractions from the Sephadex G50 column as described above. These were evaluated by 
confocal microscopy to confirm successful formation of pyranine-loaded liposomes. Imaging 
was performed in fluorescent (Figure 2-5A) and normal light (Figure 2-5B) modes, as well as 
the overlay of the two modes for comparison (Figure 2-5C). The images confirmed the 
presence of liposomes, however these appear to exclude pyranine since there is no 
fluorescence signal emitted by the particles presumed to be liposomes. 
Nonetheless, this method appeared to promote formation of greater populations of liposomes 
relative to extrusion. A liposomal preparation involving a combination of both extrusion and 
sonication to promote formation of single lamellar liposomes was attempted next. This was 
done to determine if it was possible to combine the benefit of solute encapsulation efficiency 
exhibited by extrusion with the benefit of greater liposome populations exhibited by sonication.  
 
Figure 2-5: Pyranine-loaded liposomes prepared by sonication. The lipid suspension was subjected to 
sonication for 5 minutes to promote formation of unilamellar vesicles. Excess pyranine was removed by sonication 
on a Sephadex G-50 column and the “pure” liposomes were harvested by elution with gravitational force and 
collection of 1 mL fractions. The fractions were imaged in fluorescent (A) and normal light (B) modes, as well as 
an overlay of the two (C). 
Excess pyranine was removed and pyranine-loaded liposomes harvested as described above. 
The collected fractions were once again evaluated for successful liposome formation by 
confocal microscopy and images were acquired in fluorescence and normal light modes as 
well as an overlay of the two modes (Figure 2-6). The images show more liposomes per area 
than in previous liposomal preparations. This in turn, suggests that the combination of 
extrusion and sonication does promote formation of more liposomes relative to individual 
application of these techniques. Unfortunately, these liposomes still appear to exclude the 
pyranine. This may be attributed to formation of micelles rather than unilamellar vesicles which 
may occur when a lipid suspension is subjected sonication. Since there is no way of ensuring 
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that unilamellar vesicles rather than micelles are produced by sonication, this technique was 
deemed suboptimal for preparation of solute-loaded liposomes. 
 
Figure 2-6: Preparation of pyranine-loaded liposomes by combination of extrusion and sonication. Lipid 
suspension was subjected to sonication, followed by 11 extrusion passages to promote formation of single lamellar 
vesicles. The resultant pyranine-loaded liposomes were collected by elution with gravitational force from Sephadex-
G50 to remove excess pyranine. Imaging was performed in green fluorescent (Panel A) and normal light (Panel B) 
modes as well as an overlay of both (Panel C).  
Nevertheless, as the combination of extrusion and sonication produced more liposomes, 
which in turn implies that longer processing time was key to producing liposomes from each 
preparation, the number of extrusion passages was increased from the 11 (manufacturer 
recommendation) to 20 passages to improve liposome formation efficiency. 
Once again, the excess pyranine was removed by size exclusion chromatography and the 
liposomes were harvested in 1 mL fractions by elution with gravitational force from the 
Sephadex-G50 column. Evaluation of these fractions by confocal microscopy reveals 
spherical particles that emit green fluorescence from both fractions (Figure 2-7). However, the 
first fraction had a relatively high background fluorescence signal which was subtracted to 
improve the contrast in the image (Figure 2-7 A&B). In contrast, the second fraction contained 
more liposomal particles and had a low background fluorescence signal relative to the first 
(Figure 2-7 C). No further processing was required for the image of this fraction, and the image 
was then re-captured in a zoomed position in an effort to obtain more detail about the size 
distribution of the liposomes (Figure 2-7 D). This image represents the upper magnification 
limit of the confocal microscope and demonstrates the small size of the liposomal particles. 




Figure 2-7: Pyranine-loaded liposomes prepared after 20 extrusion passages. The lipid suspension was 
subjected to 20 extrusion passages to promote formation of pyranine-loaded single lamellar vesicles. Excess 
pyranine was removed by size exclusion chromatography on a Sephadex G-50 column. The first two 1 mL fractions 
collected (Panels A, B and C, D, respectively) were imaged to confirm the presence of “pure” liposomes. This first 
fraction contained spherical particles presumed to be the liposomes (A), however the background fluorescence 
had to be subtracted to improve contrast (B). The second fraction also contained these spherical particles 
presumed to be pyranine-loaded liposomes (C). The re-captured image in a zoomed position was produced in an 
attempt to obtain more detail about liposomal size distribution (D).   
The average diameter of the liposomes was expected to be close to 100 nm140, because the 
extruder was fitted with 2 × 100 nm polycarbonate filters. This is about 20 times smaller than 
an average bacterial cell141, which is also much smaller than the smallest mammalian cell, the 
erythrocyte141. In addition to this, it was challenging to obtain a good image of the liposomes 
in solution as the particles moved around a lot due to the aqueous environment. This could 
have been resolved by fixing the liposomes to the microscope slide. However, this is additional 
processing that would also require further optimization and deviated from the objectives of the 
study and was therefore not performed.  
2.2.3 Determination of size distribution by scanning electron microscopy (SEM) 
The challenges outlined above and instrument limitations encountered necessitated switching 
to a more sensitive technique like scanning electron microscopy (SEM). As the name 
suggests; SEM is a form of electron microscopy that provides topographic detail about the 
particles in question. It has higher resolution than confocal microscopy because it uses high 
energy electrons rather than light to generate images142,143. This technique requires that the 
sample be dry during imaging which eliminates the particle movement issues observed with 
confocal microscopy.  
The liposomal preparation imaged in Figure 2-7 by confocal microscopy was also evaluated 
by SEM. The image was initially acquired in dark field mode which creates a contrast between 
light emitting and non-light emitting particles (Figure 2-8 A). This was done to identify the 
fluorescent particles presumed to be the pyranine-loaded liposomes. Subsequently, imaging 
was performed in bright field mode (Figure 2-8 B). Both images show the presence of spherical 
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particles presumed to the pyranine-loaded liposomes. The average size distribution was 
determined by measuring the diameters of some of the particles observed (Figure 2-9). The 
particles ranged in size between 50 and 100 nm which is within the expected range since the 
extruder was fitted with polycarbonate filters of 100 nm pore size.  
 
Figure 2-8: Pyranine-loaded liposomes imaged by scanning electron microscopy (SEM). The fractions were 
captured in dark field (A) and in bright field (B) modes, respectively.  
 
Figure 2-9: Size distribution of pyranine-loaded liposomes prepared by extrusion followed by size 
exclusion chromatography. The image was captured in bright field modes using SEM.  
Taken together, the observations demonstrate the feasibility of SEM for qualitative 
determination of liposome size distribution. The observations show that extrusion is useful for 
preparation of liposomes of a predetermined size. Nonetheless, there were still challenges 
encountered when imaging liposomes with this technique. A major challenge was that the 
phospholipids in the liposomes oxidized as a result to exposure to the electron beam. This led 
to darkening in the exposed areas which in turn made it difficult to obtain a good quality image. 
Imaging with Cryo-electron microscopy in which samples are imaged in a frozen state would 
have been ideal for this kind of sample142. Unfortunately, such an instrument was not readily 
available at the time of performing this study. 
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2.2.4 Harvesting the liposomes by centrifugation improves the size dispersion 
The relatively small size of the liposomes made it difficult to obtain good quality images with 
confocal microscopy. It also made it necessary to use a higher resolution technique (SEM) to 
obtain the detail that was required to determine size distribution of the particles, at least from 
a qualitative perspective. However, due to the inability to obtain good quality images it was 
decided to revert back to confocal microscopy. However, to circumvent some of the previous 
challenges liposomes of a greater diameter were prepared by fitting the extruder with 
polycarbonate filters of 800 nm pore size, which should result in liposomes with an average 
diameter of up to 800 nm140. This is relatively close to the diameter (1 000 nm) of an average 
bacterium. The liposomes were prepared as previously described, except this time the “pure” 
pyranine-loaded liposomes were harvested by low speed centrifugation in a swing bucket rotor 
instead of using size exclusion chromatography. The flow-through was collected and imaged 
in fluorescent and normal light (as well as a combination of the two) to evaluate this method 
(Figure 2-10 A-C).  
The image confirms the presence of spherical green light emitting particles presumed to be 
pyranine-loaded liposomes. It also shows more particles per area imaged relative to the 
previous preparation. This can be attributed to the method used to harvest the liposomes, 
since it is the only factor that was varied in addition to the liposomal size. 
 
Figure 2-10: Pyranine-loaded liposomes of 800 nm diameter prepared by 20 extrusion passages and 
imaged using confocal microscopy.  Imaging was performed in green fluorescent light (Panel A), normal light 
(Panel B), as well as the overlay of fluorescent and normal light (Panel C).  
2.2.5 Determining size dispersion by dynamic light scattering 
The size dispersion of the bigger liposomes preparation was determined by dynamic light 
scattering (DLS) (Figure 2-11). DLS measures the single scattering events to provide 
information on the dynamic properties of a particle144. It assumes that each detected photon 
has been scattered by the sample only once. The diameter size is indicated in nm on the x-
axis, and the relative abundance is indicated by peak intensity which is expressed as a 
percentage on the y-axis (Figure 2-11). The peak close to 100% intensity indicates that most 
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of the particles in the sample are between 500 and 800 nm diameter, suggesting that the 
majority of the particles in the sample are within the expected range. There is also a small 
shoulder at 20% intensity with a 100 nm diameter, indicating the presence of some smaller 
particles. Extrusion performed with membrane filters of a pore size greater than 200 nm tend 
to produce liposomes of a slightly smaller diameter than the membrane pore size, hence the 
observed polydispersity140. Since the majority of the population was made of liposomes within 
the expected size range, this was considered to be a reasonable size dispersion and no further 
optimisation was done. 
Taken together, these observations suggest that solute-loaded unilamellar liposomes of 800 
nm diameter can be prepared by 20 extrusion passages in a hand-held extruder fitted with 2 
polycarbonate filters of 800 nm pore size. The results also suggest that excess solute can be 
adequately removed by size-exclusion chromatography on a Sephadex G50 column prepared 
in house. Following this, the pure solute loaded liposomes can be harvested by low speed 
centrifugation to obtain liposomes of reasonable sample concentration and uniform size 
dispersion.  
 
Figure 2-11:  The size distribution of pyranine-loaded liposomes as determined by dynamic light scattering 
(DLS). The particle size is indicated as average diameter in nanometres (nm), and the intensity weighted 
distribution of particles is indicated as percentage. The symbols represent the average of value obtained from 
triplicate determination, with the error bars representing ± standard deviation. 
2.2.6 CPM-loaded liposomes are not suitable for performing permeability 
measurements 
Following the validation of the liposome preparation method, the next objective was to identify 
a suitable fluorophore for performing permeability measurements of the compounds of interest 
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in this particular study, i.e. CoA and its biosynthetic intermediates. The fluorophore selected 
for this purpose is 7-diethylamino-3-(4-maleimidophenyl)-4-methylcoumarin (CPM) (Figure 
2-12). This molecule has a low fluorescence emission—unless it forms adducts with a thiolated 
molecules. Moreover, it was also an attractive option because its sensitivity towards P-PantSH 
and CoA intermediates has already been demonstrated145. 
In addition, a reference compound also needed to be identified to be used as negative control. 
This compound should not be able to efficiently cross the membrane, but should also contain 
a free thiol to allow for its reaction with CPM. While considering compounds that would 
possibly fit this profile, we noted that a transport protein dedicated to the membrane 
translocation of glutathione (GSH) has been determined146. This suggests that GSH is 
incapable of crossing biological membranes by passive diffusion. This molecule is also a low 
molecular weight thiol similar to CoA and its intermediates (including P-PantSH, which is the 
subject of the current study). For these reasons, GSH was selected as a reference. 
CPM-loaded liposomes were prepared on the principle that no fluorescence signal would be 
observed unless the molecule interest can permeate the membrane and react with CPM to 
form fluorescent adducts inside the liposome. Since GSH is expected to be membrane 
impermeable, a control experiment was set-up by treating a fraction of the CPM-loaded 
liposomes with 0.1% Triton X-100 to “permeabilize” the liposomal membrane. GSH was 
expected to permeate the Triton-treated membrane. However, the observed outcomes show 
no distinction between intact and permeabilized liposomes (Figure 2-13). This was attributed 
to CPM apparently being membrane permeable,  which implies that the observed fluorescence 




Figure 2-12: The principle behind CPM fluorescence. CPM is a coumarin-based fluorophore that does not 
produce fluorescence unless it forms adducts with thiol molecules like PantSH or P-PantSH.  
 
Figure 2-13: Membrane permeability measurements of GSH using CPM-loaded liposomes.  A fraction of the 
liposomes was treated with Triton X-100 to “permeabilize” the liposomal membrane (red). The influx of GSH into 
the liposomes was monitored by measuring change in fluorescence intensity over time. Intact CPM-loaded 
liposomes were used as a control (black) since GSH is expected to be membrane impermeable.  
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2.2.7 A discontinuous assay for determining the membrane permeability of thiolated 
molecules  
The unexpected result that CPM is permeating the liposome prompted an adjustment in the 
experimental set-up in such a way that would circumvent this property. First, the reverse 
experimental set-up was performed by preparing liposomes with the molecule of interest, 
instead of CPM, being encapsulated in the intraliposomal cavity. Liposomes were prepared 
as described earlier for the pyranine-loaded liposomes 800 nm in diameter (2.2.4).  Next, 
membrane permeability measurements were performed in a discontinuous manner. This was 
achieved by using a dialysis membrane as a barrier between the molecule-encapsulated 
liposomal suspension and a solute-free dialysate (Figure 2-14). The liposome suspension was 
placed in the dialysis unit, and then a solution devoid of the molecule of interest was used as 
a dialysate. 
In principle, if the molecule of interest is membrane permeable, it would diffuse out of the 
liposome through liposomal membrane, then through dialysis membrane and into the 
dialysate. The diffusion would continue in that direction until there are equimolar amounts of 
the molecule on either side of the dialysis membrane. The rate of diffusion can then be 
monitored by collecting aliquots of the dialysate at different time points, and adding CPM to 
determine the amount of thiolated molecule in each aliquot. The diffusion rate can then be 
reported as a change (increase) in fluorescence intensity over time. On the other hand, if the 
molecule of interest is membrane impermeable, it would not be able to escape from the 
liposome and would be absent from the dialysate aliquots. This in turn would translate to low 
or no fluorescence signal being observed upon analysis of the aliquots (since CPM has to 
form thiol-adducts with the molecule of interest in order to produce a fluorescence signal).  
The dialysis membrane is also a semipermeable membrane, which implies that the diffusion 
rate across this membrane is subject to molecular geometry and size of the molecule in 
question. For this application, the size of the molecules is not of concern as the molecular 
weight of the compounds of interest is smaller than the dialysis membrane molecular weight 
cut off (MWCO) by several orders of magnitude. However, these molecules do differ in 
geometry and polarity, and will therefore have distinct diffusion rates. These differences are 
then accounted for by determining the diffusion rate of the “free” molecule (i.e. the diffusion of 
the molecule across the dialysis membrane when it is not encapsulated in a liposome) in a 
similar manner to what is described above. The ratio of the liposomal diffusion rate described 
above, and “free” diffusion rate, is then considered as the relative liposomal diffusion ratio. 
This, in turn, is used to establish whether or not a molecule is membrane permeable. More 
specifically, the more similar the two rates are (i.e. the closer the ratio is to one), the more 




Figure 2-14: The principle behind the discontinuous assay for measuring membrane permeability of P-
PantSH and other CoA-related thiolated small molecules.  Liposomes are prepared with the solute of interest 
loaded in the lumen. The solute-loaded liposomes are placed inside the dialysis device, which is suspended in a 
solution devoid of the solute of interest (the dialysate). The diffusion rate of free metabolite (A) is measured 
concurrently with the liposomal diffusion rate (B) by taking aliquots of the dialysate at different time points. CPM is 
then added to the aliquots to determine the diffusion rate. The liposomal diffusion rate is then normalised relative 
to the free metabolite’s diffusion rate in order to describe the relative permeability of the molecule in question.  
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2.2.8 Permeability measurements of GSH using a CPM-fluorescence based 
detection method: A control experiment 
GSH was expected to have low relative liposomal diffusion since it is has a dedicated 
transporter and is therefore presumed to inefficiently permeate membranes by passive 
diffusion148–150. For this reason, GSH was selected as a reference molecule for determining 
the membrane permeability of the molecules of interest. However, its suitability for this 
purpose had to first be validated using the membrane permeability assay described above. 
GSH-loaded liposomes were prepared as described earlier for the pyranine-loaded liposomes 
800 nm in size (section 2.2.4).  In addition, 1 mM GSH and 1.5 mM TCEP (non-thiol containing 
reducing agent) was added to the liposomal suspension prior to performing extrusion. This 
was done so that GSH-loaded unilamellar vesicles could be prepared. An aliquot of the same 
solution was also used to determine the diffusion rate of “free” GSH. The liposomal diffusion 
of this molecule was then monitored as described in the work-flow depicted in Figure 2-15. 
The diffusion rate of free GSH was also monitored concurrently. CPM was then added to all 
aliquots collected and the fluorescence intensities were plotted against time to show the 
progression of the diffusion.  
A continual increase in fluorescence intensity was observed for free GSH (Figure 2-16). This 
was expected since as the MWCO of the dialysis membrane was 7 kDa which exceeds the 
size of GSH and would therefore allow free diffusion of the dialysis membrane. On the other 
hand, very low fluorescence signals were observed for the diffusion of liposomal-encapsulated 
GSH relative to the diffusion of the free metabolite. These observations suggest that the 
liposomal membrane is a physical barrier that GSH cannot overcome, and in turn that it cannot 
diffuse over the dialysis membrane. To confirm this, a fraction of the GSH-loaded liposomes 
was treated with Triton X-100 to permeabilize the liposomal membrane. The GSH diffusion 
from these permeabilized liposomes was also monitored and then plotted as fluorescence 
intensity as a function of time. The results show that GSH could diffuse over this compromised 




Figure 2-15: Work-flow for the discontinuous assay for measuring the membrane permeability of thiolated 
small molecules. A solution containing the molecule of interest is used to hydrate the lipid film (1), the resultant 
lipid suspension is the subjected to 20 extrusion passages to promote formation of unilamellar vesicles loaded with 
the molecule of interest (2), the diffusion of the molecule from the liposome is then measured discontinuously by 
placing the liposomal preparation inside a dialysis unit then collecting aliquots at different time points (3), CPM is 






Figure 2-16: Membrane permeability measurements of glutathione (GSH).  The diffusion rates of free GSH 
(red), and liposome-loaded GSH (black), were determined in a discontinuous manner by collecting aliquots at 
different time points. The diffusion rate of GSH from liposomes treated with 0.1 % Triton X-100 (Green) was also 
determined. The diffusion rate is depicted as an increase in fluorescence intensity of CPM-GSH adducts over time. 
Taken together, these observations suggest that the liposome is a physical barrier that mimics 
biological membranes in its ability to exclude molecules that are inherently membrane 
impermeable. The observations further confirm the suitability of GSH as a reference molecule 
for permeability measurements of thiolated metabolites (such as P-PantSH and other related 
molecules) and validates the adjusted experimental set-up as a viable method to optimize for 
further permeability studies. 
2.2.9 The detection method can be changed to accommodate a diverse selection of 
molecules 
As previously mentioned, the reactivity of CPM towards P-PantSH and other CoA 
intermediates has been demonstrated and further confirmation is therefore not required145. 
However, to optimize the permeability assay further, the “free” diffusion rates of the molecules 
of interest had to be determined using CPM-based fluorescence as a detection method (Figure 
2-17). In addition to GSH and P-PantSH, the diffusion rates of PantSH, dePCoA, N-
acetylcysteamine (H-SNAC), and CoA were be determined using a CPM-based fluorescence 
detection method. This further demonstrates the suitability of this fluorophore for use in 




Figure 2-17: The diffusion rates of 1 mM GSH, P-PantSH, and other thiolated CoA intermediates through 
the Slide-A-Lyzer® mini-dialysis membrane (MWCO = 7 kDa, Thermo scientific, U.S.A). The diffusion rates 
were the determined using the CPM-based fluorescence assay to determine the suitability thereof for application 
as a detection method in a membrane permeability assay. The experiment was performed twice (n = 2), each in 
triplicate. The bar indicates the average of the two experiments, and the error indicates the range/2 (i.e., the upper 
and lower limits of the range as determined). 
As CPM is only suitable for thiol molecules and thereby not applicable to other kinds of 
molecules, the permeability assay is set up in such a manner that it is possible to change the 
detection method without changing the fundamental principles on which the assay is based. 
This implies that the fluorophore can be replaced as required to accommodate molecules with 
a variety of structural features or different structural diversities. However, the important 
requirements to consider is a suitable molecule to use a reference, as well the sensitivity of 
the detection method towards all molecules in question. The latter can be confirmed by 
measuring the “free” diffusion of the molecules using the detection method in question to find 
out if all the molecules are detectable. 
The molecules of interest in the current study could be divided into three classes: thiolated 
CoA intermediates for which CPM was used as part of the detection method; structural 
analogues of PanCOOH that can act as substrates for a PanK-coupled enzyme assay utilizing 
NADH consumption as detection method, and finally phosphorylated PanCOOH analogues 
that are substrates for alkaline phosphatase (ALP) coupled to a malachite green assay that 
could be used as a detection method. 
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2.2.9.1 PanK-coupled enzyme assay as a detection method 
The PanCOOH analogues selected for the current study are all substrates for PanK – the 
enzyme that catalyzes the first reaction of CoA biosynthesis105. A pyruvate kinase-lactate 
dehydrogenase (PK-LDH)-coupled enzyme assay for determining catalytic activity of PanK 
has been previously described  and used routinely for mechanistic studies of PanK (Figure 
2-18)151. Therefore, this assay was selected as a detection method in the current study since 
it required no further optimization and PanCOOH analogues selected for the current study are 
all substrates for PanK. In this assay PanK-mediated phosphorylation of PanCOOH analogues 
takes place in the presence of ATP-hydrolysis to ADP. This reaction is then coupled to the 
production of lactate from phosphoenolpyruvate (PEP) via pyruvate as catalyzed by PK and 
LDH. The latter requires NADH as a cofactor and its consumption can be monitored 
spectrophotometrically at 340 nm.  
 
Figure 2-18: Principle behind the PK-LDH coupled enzyme assay for determining PanK activity. The 
phosphorylation of PanCOOH to P-PanCOOH is mediated by PanK. This reaction is coupled to ATP hydrolysis 
and the resultant ADP is used as cofactor for the conversion of PEP to pyruvate (Pyr) which is mediated by pyruvate 
kinase (PK). The pyruvate is reduced to lactate by lactate dehydrogenase (LDH), and this is coupled to NADH 
oxidation. NADH is chromogenic and the oxidation can be monitored at 340 nm on a spectrophotometer. 
If the molecule of interest is present in the aliquots collected to monitor the rate of diffusion, 
PanK can be used to determine the concentration of PanCOOH and most compounds 
retaining the pantoyl moiety (Figure 2-19). In this manner, the rate of NADH consumption 
corresponds to the amount of “substrate” in each aliquot. The diffusion rates can then be 




Figure 2-19: Detection method can be changed without changing the experimental set-up for the 
discontinuous assay for measuring membrane permeability. The detection assay can be changed to 
accommodate diverse chemical and structural diversities, which in turn makes the assay versatile: For 
determination of diffusion rates of pantothenate and its selected structural analogues, instead of using CPM (step 
4) the detection method is changed to a PanK-coupled enzyme assay which monitors NADH consumption. 
PanCOOH is the natural substrate for PanK and since a dedicated transporter has been 
characterized for this molecule73,152, it is also presumed to be incapable of membrane 
permeation by passive diffusions similar to GSH. For these reasons, it was selected as a 
negative control for molecules studied by the PanK coupled enzyme assay. The diffusion rates 
of free PanCOOH and pantothenate analogues of interest in the current study were 
determined by the described discontinuous assay (Figure 2-20). The figure shows the diffusion 
rates of PantSH, PantOH, N5-Pan and N-phenethylpantothenamide (N-PE-Pan) in addition to 
that of PanCOOH, this in turn confirms suitability of the coupled enzyme assay as a detection 




Figure 2-20: The diffusion rates of 1 mM PanCOOH, PantSH, PantOH, N5-Pan and N-PE-Pan through the 
Slide-A-Lyzer® mini-dialysis membrane (MWCO = 7 kDa, Thermo scientific, U.S.A). The diffusion rates were 
the determined using the PanK-coupled enzyme assay which monitors NADH consumption to determine the 
suitability thereof for application as a detection method in a membrane permeability assay. The experiment was 
performed twice (n = 2), each performed in triplicate. The bar indicates the average of the two experiments, and 
the error indicates the range/2. 
2.2.9.2 Alkaline phosphatase-malachite green coupled assay as a detection method 
ALP is an enzyme that cleaves phosphate esters to liberate inorganic phosphate groups153. 
The cleavage reaction can be monitored spectrophotometrically using the malachite green 
dye which undergoes a color change in the presence phosphates and is detected at 620 nm 
(Figure 2-21)154,155.  
Similar to the two assays a negative control had to be identified for this assay. Glucose-6-
phosphate (G6P) is a small molecule for which a dedicated transporter has been characterized 
in eukaryotes and prokaryotes156,157. Therefore, this molecule should also be unable to cross 
membranes by passive diffusion. Furthermore, this molecule may be a substrate for ALP, and 
for these reasons it was selected as reference molecule for the membrane permeability 




Figure 2-21: The principle behind the ALP-malachite green coupled assay. ALP cleaves the phosphorylated 
substrate and the amount of phosphate that is liberated is determined spectrophotometrically through its interaction 
with malachite green dye which undergoes a colour change in the presence of phosphates. The observed changes 
can be attributed to their rate of diffusion across the dialysis membrane. 
G6P is structurally unrelated to the P-PanCOOH analogues that are of interest in this assay, 
and the activity of ALP towards G6P and the molecules of interest had to be determined to 
confirm compatibility with the assay conditions (Figure 2-22). In addition, a chromogenic 
molecule, p-nitrophenyl phosphate (pNPP), is commonly applied as a positive control for ALP-
based assays and was included for this purpose.  
 
Figure 2-22: Chemical structures of G6P and P-PantSH to illustrate the difference in composition. 
The activity of ALP towards pNPP was used as a reference to compare relative activity 
towards G6P and P-PantSH (Figure 2-23). The figure shows that the ALP could cleave both 
G6P and P-PantSH with similar efficiency to pNPP cleavage. This shows that the enzyme has 
relaxed substrate specificity and is therefore suitable for application in the context of this study.  
Once ALP activity was confirmed, selected analogues including phospho-N-
pentylpantothenamide (P-N5-Pan), phospho-N-phenethylpantothenamide (P-N-PE-Pan), and 
4′-phosphopantothenate (P-PanCOOH) as well as 4′-phosphopantothenol (P-PantOH) were 
used to evaluate the suitability of the ALP-malachite green assay for application as a detection 
method in the membrane permeability assay using liposomes. The diffusion rates were 
reported as a change in absorbance as a function of time in minutes (Figure 2-24). The rates 
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for all six molecules could be determined which indicates the suitability of the ALP-malachite 
green coupled assay as a detection method for discontinuous measurement of the membrane 
permeability of P-PantSH and selected phosphorylated pantothenate analogues.  
 
Figure 2-23: ALP has relaxed substrate specificity and can cleave G6P and P-PantSH with similar efficiency 
to pNPP. The activity of ALP towards G6P and P-PantSH was evaluated using activity towards pNPP as a control. 
The experiment was performed twice (n = 2), each in triplicate. The bar indicates the average of the two 
experiments, and the error indicates the range/2. 
 
Figure 2-24: The diffusion rates of 1 mM G6P, P-pantSH, P-N5-pan, P-N-PE-pan, P-panCOOH and P-pantOH 
through the Slide-A-Lyzer® mini-dialysis membrane (Thermo scientific, U.S.A). The diffusion rates were the 
determined using the ALP-malachite green coupled assay to determine its suitability thereof for application as a 
detection method in a membrane permeability assay. The experiment was performed twice (n = 2), each in 




Small molecule permeability is an important but often neglected aspect of drug discovery. The 
lack of fundamental understanding of the molecular determinants of membrane permeability 
in small molecules is brought about in part by the scarcity of adequate investigatory tools. This 
challenge is further compounded by the overwhelming diversity chemical compounds that 
could serve as potential drug candidates. In an effort to address this issue we have described 
a liposome-based discontinuous assay for measuring membrane permeability of small 
molecules – with particular focus on CoA related molecules. The assay is set up in such a 
manner that the detection methods used to identify the molecules of interest can be changed 
as required to accommodate chemically and structurally diverse molecules. The use of 
liposomes as a membrane model also means the assay in amenable and can be used to study 
membrane permeation by passive diffusion as well as by protein mediated transport.  
2.4 Materials and methods 
The following reagents purchased from Sigma-Aldrich, Germany were all buffer grade, at 
purity of 95% or higher pantothenic acid (PanCOOH), pantethine, dephospho-CoA (dePCoA), 
coenzyme A (CoA), MES (2-(N-morpholino)ethanesulfonic acid), sodium chloride (NaCl), 
tris(2-carboxyethyl) phosphine (TCEP), potassium chloride (KCl), Tris, magnesium chloride 
(MgCl₂ , calcium chloride (CaCl₂ , ammonium molybdate and Triton X-100. This is with the 
exception of the following: pyranine  and malachite green* (microscopy grade, *1% stock 
solution), 7-diethylamino-3-(4-maleimidophenyl)-4-methylcoumarin (CPM), adenosine-3',5'-
triphosphate (ATP) and glutathione (GSH) which were HPLC grade, p-nitrophenyl phosphate 
(pNPP), glucose-6-phosphate (G6P) and (phospho-enol pyruvate) PEP which were enzyme 
assay grade. Cholesterol and 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) were 
Sigma grade. Chloroform and ethanol were HPLC grade with 99% purity and were both 
purchased from Merck Germany. HCl was also purchased from Merck, Germany. PK from 
rabbit muscle (10 mg/ml), LDH from pig heart (10 mg/ml), ALP from calf intensitine (10 mg/ml), 
BSA as well as NADH (Laboratory grade at 98% purity) were all from Roche, Germany. PanK 
from Escherichia coli (EcPanK) was obtained by heterologous expression with a histidine tag 
followed by Immobilized metal affinity chromatography (IMAC) purification according to 
previously published methods99. Polycarbonate membrane filters were from Whatmann. The 
hand-held mini-extruder was from Avanti Polar Lipids®, U.S.A. Sephadex-G50 were from 
Amerscham, UK. 96-well black and clear plates used for fluorometry and spectrophotometry, 
respectively, were from Thermo Scientific, U.S.A. The Haereus benchtop swing bucket 
centrifuge is manufactured by Thermo Scientific, U.S.A. The Power sonic 405 sonication bath 
is manufactured GT sonic, U.S.A. The Slide-A-Lyzer® mini-dialysis membrane units were from 
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Thermo scientific, U.S.A. The rest of the phosphorylated and non-phosphorylated 
pantothenate analogues were chemically synthesised in-house by Dr. Leanne Barnard. 
2.4.1 Lipid stock preparation 
Lipid stocks of cholesterol and POPC were prepared by weighing out the dry lipid powder and 
dissolving it in chloroform to a concentration of 10 mg/mL for each compound. From each 
stock, a 1 mL aliquot was transferred to a round bottom flask after which the organic solvent 
was removed in vacuo. Residual solvent was removed under high vacuum for a period of 12 
hours.  
2.4.2 Preparation of pyranine-loaded liposomes by extrusion 
A solution of 100 μM Pyranine in 20 mM MES (pH 5.9) and 180 mM NaCl was used to hydrate 
the dry lipid film. The resultant liposome suspension was subjected to 10 cycles of freezing at 
-80 ̊ C (in liquid nitrogen) and thawing at room temperature to promote formation of unilamellar 
vesicles. Following this, the suspension was subjected to 11 or 20 extrusion passes on the 
mini-extruder fitted with 2 × 0.1 μm diameter polycarbonate membrane filters. Filter 
membranes were included to promote formation pyranine-loaded liposomes. Excess pyranine 
was removed by size exclusion chromatography using a Sephadex-G50 column prepared in-
house. To prepare the column, 2 g of Sephadex-G50 beads was weighed out and hydrated 
with 20 mM MES (pH 5.9) and 180 mM NaCl. The slurry was allowed to stand at room 
temperature for 1 hour for full hydration of the beads. The excess buffer was decanted out and 
the slurry was transferred to a 5 mL syringe column sealed with cotton wool. The column was 
then placed in a 15 mL centrifugal tube and the beads were packed by centrifugation at 3 000 
g for 5 minutes in a benchtop swing bucket centrifuge. The residual buffer collected in the flow 
through and was discarded. The extruded lipid suspension was then placed on the column 
bed. The pyranine-loaded liposomes were then eluted and collected in 0.5 mL or 1 mL 
fractions with 20 mM MES (pH 5.9) buffer containing 180 mM NaCl (from here on called "MES-
NaCl”). 
2.4.3 Preparation of pyranine-loaded liposomes by sonication 
The liposome suspension was subjected to freeze-thaw cycles as described in 2.4.2. 
However, instead of promoting liposomal formation with extrusion, the suspension was 
electrosonicated for 5 minutes, in a sonication bath at 10 °C. The excess pyranine was then 
removed as described in 2.4.2. 
2.4.4 Preparation of pyranine-loaded liposomes of 800 nm diameter 
The liposomes were prepared as described 2.4.2 except that the extruder was fitted with 2 × 
polycarbonate filters of 800 nm diameter. Furthermore, the liposomes were harvested from 
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the Sephadex-G50 column by centrifugation at 1000 g for 5 minutes in the benchtop swing 
bucket centrifuge. The pure liposomes were then collected in the flow-through. 
2.4.5 Preparation of the GSH-loaded liposomes 
The lipid film was prepared as described in Error! Reference source not found.. However, 
the film was hydrated with a solution of 1 mM GSH containing 1.5 mM TCEP. The resultant 
lipid suspension was subjected to freeze-thaw cycles as described for 2.4.2. Following this, 
the suspension was subjected to 20 extrusion passes on the mini-extruder fitted with 2 × 800 
nm diameter polycarbonate membrane filters. This was done to promote formation of GSH 
loaded liposomes. Excess GSH was removed by size exclusion chromatography in a 
Sephadex-G50 column prepared in-house as described in 2.4.2, except the slurry was 
hydrated with MilliQ water instead of the MES-NaCl buffer. The GSH-loaded liposomes were 
then harvested by centrifugation as described in 2.4.4. 
2.4.6 Confocal microscopy 
Liposome imaging was performed on the Carl Zeiss LSM 780 confocal microscope housed in 
the cell imaging unit of the Central Analytical Facility (CAF) available at Stellenbosch 
University. The objective used was Alpha Plan-Apochromat 100x/1.46 Oil DIC M27. The light 
source used was an argon multiline laser 25 mW and the ~400/~480 nm emission filter was 
used to acquire the image.   
2.4.7  Scanning Electron Microscopy (SEM) 
Liposome imaging was performed on the Zeiss MERLIN SEM microscope housed at the 
Electron beam unit of CAF, Stellenbosch University. The following parameters were set for 
imaging: probe I = 250 pA, EHT = 200 keV and WD = 3.4 mm. 
2.4.8  Dynamic light scattering 
The size distribution of the unilamellar vesicles was determined by dynamic light scattering on 
the Malvern Zetasizer version 7.11 housed at Kansai Plascon in the Department of Chemistry 
and Polymer Science of Stellenbosch University. A 12 μL aliquot of the pyranine-loaded 
liposomal preparation was used to determine the size distribution. Water was used as a 
dispersant. Thus, 12 μL of the liposomal preparation was dissolved in water to a final 
concentration of 1 mL. The measurements were performed in a disposable sizing cuvette of 1 
cm path length. The instrument temperature was set to 25 °C. The measurements were 
acquired at a count rate of 364.3 counts.sˉ¹ with an average acquisition time of 60 s. The 
attenuator index was set at 7 such that 1% of the laser light could penetrate the cuvette.  
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2.4.9 Membrane permeability measurements of GSH using the CPM-based 
continuous liposomal assay 
The lipid film was prepared as described in 2.4.1 However, the film was hydrated with a 
solution of 50 μM CPM to a final lipid concentration of 10 mg/ml. The resultant lipid suspension 
was subjected to freeze-thaw cycles as described for 2.4.2. Following this, the suspension 
was subjected to 20 extrusion passes on the mini-extruder fitted with 2 × 800 nm diameter 
polycarbonate membrane filters. This was done to promote formation of CPM loaded 
liposomes of 800 nm diameter. Excess CPM was removed by size exclusion chromatography 
in a Sephadex-G50 column prepared in-house as described in 2.4.2, except the slurry was 
hydrated with MilliQ water instead of the MES-NaCl buffer. The CPM loaded liposomes were 
then harvested by centrifugation as described in 2.4.4.  
A 200 μL aliquot of CPM-loaded liposomes was then treated with 0.1 % Triton X-100. This 
aliquot, together with an aliquot of the intact CPM loaded liposomes were transferred to a 96-
well plate. The GSH solution (stock solution 10 mM) was added to a final concentration of 1 
mM in both the intact and the permeabilized CPM-loaded liposomes. The GSH influx into the 
liposome was then determined by monitoring the change in fluorescence intensity of CPM at 
1 minute intervals for about 20 minutes. This experiment was performed on a TECAN spark 
10M fluorimeter (Switzerland) where fluorescence emission was monitored at λex = 387 nm 
and λem = 465 nm. The fluorescence signal was optimised for 1 mM GSH.  
2.4.10 Membrane permeability measurements of GSH using the discontinuous 
membrane permeability assay 
A 1 mM GSH solution was prepared to represent the “free” GSH. Three dialysis membrane 
units were hydrated for 10 minutes in 3 × 10 mL beakers filled with 900 μL of MilliQ water 
each. Following hydration, 200 μL of the GSH-loaded liposomes were placed inside the first 
dialysis unit and 200 μL 1 mM GSH solution was added the second dialysis unit to measure 
liposomal diffusion of “free” GSH. For the “permeabilized” liposome experiment a 500 μL 
aliquot of the liposomal suspension was treated with 0.1% Triton X-100 (this 5 μL of 10% Stock 
solution. Following this, 200 μL of this detergent-treated liposomal preparation was placed in 
the last dialysis unit. The respective diffusion rates were then monitored by collecting 20 μL 
aliquots of the dialysate at 1 hour intervals for 8 hours. The aliquot was then transferred to a 
black 96-well plate to which 160 μL MilliQ water and 20 μL of CPM (10 μM) were added. The 
plate was then incubated at room temperature for 30 minutes to allow formation of CPM-
adducts. Following this, the fluorescence intensity of each aliquot was measured on the 
TECAN spark 10M fluorimeter (Switzerland) at λex = 387 nm and λem = 465 nm. The signal 
was again optimised to 1 mM GSH. The fluorescence intensity values were then plotted 
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against time intervals to illustrate GSH diffusion. The diffusion rates were then determined by 
calculating the slopes of respective plots.  
2.4.11 Determination of small molecule diffusion rates using PanK-PK-LDH based 
discontinuous liposomal assay 
Solutions of PanCOOH and selected PanCOOH analogues (N5-Pan, N-PE-Pan, PantSH and 
PantOH) were prepared to a final concentration of 5 mM each. Following this, 900 μL of water 
was placed in 3 × 10 mL beakers. Dialysis membranes were placed in each beaker and 
allowed to hydrate for 10 minutes. Following this, 200 μL of 1 mM PanCOOH solution was 
placed in the respective dialysis membrane unit such that there were three replicates. Aliquots 
of 20 μL dialysate were collected at 1 hour intervals for 5 hours and transferred to a 96-well 
plate. This process was repeated for each pantothenate analogue. A reaction mixture of 1.5 
mM ATP, 2 mM PEP, 0.5 mM NADH, EcPanK (2 μg/200 μL reaction), 2 U PK, 2 U LDH was 
prepared in a 50 mM Tris-HCl (pH 7.4) buffer containing 20 mM KCl and 20 mM MgCl₂. The 
presence of PanCOOH (or other analogues of interest) in each aliquot was determined by 
adding 180 μL of the reaction mixture and monitoring change in absorbance at 340 nm to 
determine NADH consumption from each aliquot. Each experiment for each of the analogues 
of interest was performed twice.  
The coupled enzyme assay is set up in such a manner that the NADH consumption rate 
corresponds to the amount of PanCOOH (or other pantothenate analogues) used as a 
substrate for the PanK reaction. For this reason, the resultant NADH rates obtained for each 
aliquot were plotted against the time interval at which the aliquot was collected to represent 
the diffusion of the metabolite of interest over time. The slopes of these time courses were 
then used to calculate the diffusion rate of each of the metabolites investigated. 
2.4.12 Determination of small molecule diffusion rates using the ALP-malachite 
green based discontinuous liposomal assay 
Solutions of G6P, P-PantSH, and the selected phosphorylated PanCOOH analogues were 
prepared to a final concentration of 5 mM each. Following this, 900 μL of water was placed in 
3 × 10 mL beakers. Dialysis membranes were placed in each beaker and allowed to hydrate 
for 10 minutes. Following this, 200 μL of 1 mM G6P solution was placed in each dialysis unit 
such that these were replicates. Aliquots of 20 μL dialysate were collected at 1 hour intervals 
for 5 hours and transferred to a 96-well plate. The experiment was performed twice for each 
molecule of interest. To determine the diffusion rate, a phosphate cleavage reaction was 
prepared by adding 4 mM NiCl₂, 50 mM Tris-HCl (pH 7.6), 0.1 mM CaCl₂, BSA (2 mg/mL) and 
5 U ALP  to each 20 μL aliquot to a final volume of 100 μL. Each reaction mixture was 
incubated at 37 °C for 2.5 h to allow cleavage of the phosphorylated compound by ALP. 
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Following this, the enzyme was heat-inactivated at 65 °C for 15 minutes. The reaction 
components were then removed by centrifugation at 13 000 g for 5 minutes. The supernatant 
from each aliquot was transferred to a 96-well plate. To determine the amount of phosphate 
in each aliquot, 50 μL of a malachite green solution (0.034 (v/v) % malachite green, 3.4 (v/v) 
% ethanol, 10 mM ammonium molybdate dissolved in 1 M HCl) was added to each well. The 
plate was allowed to stand at room temperature for 10 minutes for color development. The 
absorbance for each aliquot was measured at 625 nm and plotted against time to show the 
diffusion of each molecule of interest over time. The slopes of the resultant plots were then 
used to calculate the diffusion rate for each molecule of interest. 









3 Membrane permeability studies of 4'-phospho-
pantetheine (P-PantSH) and selected pantothenate 
analogues 
3.1 Introduction 
Observations from a nutrient complementation study in Drosophila S2 cells as well as PAMPA 
permeability screens suggested that P-PantSH has the ability to enter membranes unaided158.  
In this context, this part of the study seeks to identify the molecular determinants that confer 
permeability by passive diffusion by attempting to answer the following questions: What are 
the specific structural components that enable P-PantSH to cross membranes? And, are there 
specific membrane constituents that enable permeation by passive diffusion? Two 
approaches were used to attempt to answer these questions. The first investigated the 
structure-permeability relationship with a view of understanding the importance and relevance 
of particular aspects of the chemical structure of P-PantSH and its analogues that promote 
permeability. The second investigated the membrane fluidity-permeability relationship and 
focused on how differences in membrane composition influence the permeability of these 
membranes to P-PantSH. Together, these investigations attempted to improve our 
understanding of the interplay of molecular structure, membrane composition and 
permeability. 
 Structure-permeability relationship  
The structure of P-PantSH has three distinct components that may play a role in the ability of 
this molecule to translocate membranes. These are a 4’-phosphate group, a pantoyl moiety 
and a cysteamine moiety (Figure 3-1 1). Analogues that differ from P-PantSH in at least one 
of these moieties were selected for membrane permeability studies. This was done to 
determine if there was any correlation between a specific structural component and the ability 
of the molecule to permeate a specific membrane. The membrane impermeability of CoA is 
always assumed based on the view that charged molecules cannot cross membrane unaided, 
but is yet to be demonstrated experimentally108. For that reason, CoA as well as its immediate 
biosynthetic precursor, dePCoA, were also included in the study.  
 Membrane fluidity-permeability relationship 
There are various techniques that can be used to determine membrane fluidity. These include: 
 spectroscopic techniques such as nuclear magnetic resonance (NMR) and Fourier 
transform infrared spectroscopy (FTIR)159,160,  
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 small angle scattering of X-rays  and neutrons  (SAXS and SANS, respectively) which 
is based on the deflection of parallel rays of radiation away from a straight trajectory 
following interaction with structures much larger the wavelength of the radiation161,162,  
 differential scanning calorimetry (DSC) in which the difference in the amount of heat 
required for increasing the temperature of a sample and reference is measured as a 
function of temperature, with both the sample and reference maintained at a same 
temperature approximately throughout the experiment161.  
 membrane binding dyes that  are sensitive to the polarity of their environment, such 
as 6-Propionyl-2-Dimethylaminonaphthalene (Prodan) and its variants163,164. 
 
Figure 3-1: Pantothenate analogues selected to investigate the structure-permeability relationship of P-
PantSH. Compounds 2 and 3 represent non-phosphorylated and cysteamine comparator of 1.  4 and 5 and pantoyl 
analogues of 1 and 8 and 9 are their respective non-phosphorylated analogues. 6 and 7 are analogues of 1 that 
vary in the cysteamine moiety, and 10 and 11 are the respective non-phosphorylated forms thereof. 
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In this study, membrane fluidity was studied using Prodan based on its availability, ease of 
use and the ability to easily perform the same analysis on a wide range of different systems. 
The mechanism of the Prodan-based assay will be explained in more detail in the next section. 
It was used to investigate the membranes used as models, as well as how the presence of P-
PantSH and selected pantothenate analogues impact on membrane fluidity. Solubility-
diffusion theory suggests a close relationship between fluidity and membrane permeability by 
passive diffusion as saturated phospholipids with cylindrical geometry such as 
phosphatidylcholine tend to produce relatively rigid membranes, while the presence of mono- 
and poly-unsaturated fatty acyl chains and cholesterol tend to make membrane more fluid. 
This relationship between phospholipid composition and fluidity in turn implies a relationship 
between phospholipid composition and permeability. 
For this reason, we used a membrane model that mimics the membrane composition of a 
eukaryotic membrane. We also included a model membrane that mimics the composition of a 
bacterial membrane since bacterial membranes have distinct phospholipid compositions and 
therefore are most likely to have membranes with different fluidity from those of eukaryotic 
membranes. Bacterial membranes also tend to be negatively charged at physiological pH 
because of the presence of lipid constituents such as cardiolipin (CL). Therefore, comparing 
P-PantSH permeability across the two types of membrane models may aid in identifying 
specific molecule-phospholipid interactions that may be of importance. These interactions may 
in turn be useful for devising strategies to improve permeability of potential drug molecules 
such as the PanAms that have potential for antimicrobial drug development.  
3.2 Results 
 Strategy used to perform membrane permeability measurements 
The objective of this part of the study was to measure the membrane permeability of P-
PantSH, selected pantothenate analogues, dePCoA and CoA across eukaryotic and bacterial 
membrane models. The eukaryotic membrane is typically asymmetric with sphingomyelin and 
phosphatidylcholine as the major constituents of the outer leaflet, and phosphatidylserine and 
phosphatidylethanolamine abundantly observed in the inner leaflet25. Furthermore, the 
presence of sterol lipids in eukaryotic membranes is another factor that distinguishes these 
membranes from bacterial ones. Cholesterol (Chol) is the typical sterol lipid found in 
mammalian cell membranes25,160. However, the typical distribution of this molecule in the 
membrane is poorly understood. Nonetheless, these illustrate the complexity of the 
mammalian cell membrane composition.  
In this study we asked fundamental questions regarding the membrane permeability of P-
PantSH, and we wanted a simple yet biologically relevant model to help us understand the 
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manner in which this process occurs. Within this context we selected phosphatidylcholine and 
cholesterol as a simplified form of the outer leaflet of the eukaryotic cell membrane. The major 
fatty acyl chains of the phospholipids of eukaryotic membranes are palmitic acid (16:0) and 
oleic acid (18:1) and therefore 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphophatidylcholine 
(POPC) was selected as the phospholipid component of the membrane, such that the 
composition of the eukaryotic membrane model was POPC-Chol25,28.  
The phospholipid composition of the bacterial comparator represented the cytoplasmic 
membrane of E. coli. The main component of this membrane model is phosphatidyl-
ethanolamine, which is a zwitterion like phosphatidylcholine but carries a slight negative 
charge at physiological pH165. The behaviour of this phospholipid is largely influenced by 
neighbouring lipids, and homogenous compositions thereof are non-bilayer forming. In the 
model used in the study the second major constituent of the bacterial membrane model was 
phosphatidylglycerol which also has a negative charge, and similar conical geometry to 
phosphatidylethanolamine166. The other constituent is CL which is derived from 
phosphatidylglycerol and may also carry a negative charge at physiological pH167. The 
properties of these lipids in turn give rise to a negative charge on the surface of the bacterial 
membrane model used in this study. 
For the sake of simplicity and ease of comparison, the same fatty acyl chain composition was 
used for the phospholipids of the bacterial membrane model such that the head groups were 
the main distinguishing factor between the membranes, apart from the addition of cholesterol 
in  the case of the eukaryotic membrane.Therefore, liposomes made up of POPC-Chol were 
used as the in vitro eukaryotic membrane model, and those made up of 1-palmitoyl-2-oleoyl-
sn-glycero-3-phosphoethanolamine (POPE),1-palmitoyl-2-oleoyl-sn-glycero-phosphoglycerol 
(POPG) and cardiolipin (i.e. POPE-POPG-CL) were used as the E. coli (Gram-negative 
bacterial) membrane model. The diffusion rates of the molecules of interest were determined 
by using the discontinuous assays described in chapter 2. Specifically, liposomes loaded with 
a molecule of interest were prepared and the liposomal diffusion measured for liposomes of 
both membrane models by taking aliquots at set time points and determining the concentration 
of the molecule of interest present in the aliquot (Figure 3-2). These measurements were all 
performed in triplicate. The process was repeated twice for each molecule of interest. 
The molecules of interest were divided into thiolated, phosphorylated and non-phosphorylated 
compounds, and the diffusion rates were in each case determined using the detection method 
most appropriate to each group. The following assays were performed in each case:  
A. For thiolated molecules, the assay used was based on the reaction of CPM, which 
forms fluorescent adducts with thiol molecules. 
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B. For phosphorylated compounds, alkaline phosphatase (ALP) was used since the 
amount of inorganic phosphate produced from cleavage of the phosphates can be 
determined spectrophotometrically by a malachite green dye. 
C. Non-phosphorylated analogues of pantothenate are substrates for PanK-mediated 
phosphorylation, which can be monitored by a coupled enzyme assay in which NADH 
consumption is measured spectrophotometrically. 
In all cases, the concentrations of the molecule of interest at each time point was used to 
determine the rate of diffusion from the liposome. This rate was compared to the rate of “free” 
diffusion, i.e. the rate of diffusion of the molecule of interest from a liposome-free solution 
across the dialysis membrane. Since both the free diffusion and liposome-loaded diffusion 
rates were determined twice, the ratios of the lowest and highest values obtained in each case 
provides upper and lower limits of the relative liposomal diffusion. For reporting purposes, all 
results in this section will report the average of these two limiting values, with the limits being 




Figure 3-2: Strategy used to investigate membrane permeability of P-PantSH and selected pantothenate 
analogues. A:the free (1) and liposome (2) loaded diffusion across the dialysis membrane was measured by 
collecting aliquots of the dialysate at different time points (3),  based on the identity of the molecule of interest, one 
of the three detection methods (A-C) was then for the detection of the molecule of interest in each aliquots(4). B : 
the relative liposomal diffusion rate was determined by calculating the lowest and highest possible ratios of the free 
and liposomal diffusion rates, the average ratio was then calculated from this, such that the relative liposomal 
diffusion was and an average of range of possible ratios (5). 
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 Confirmation of the liposomal encapsulation efficiency 
The membrane permeability assay was set up in such a manner that the liposomal diffusion 
rate had to be reported relative to the free metabolite diffusion rate to factor in the variation 
brought about by the dialysis membrane. The liposomal encapsulation efficiency was 
determined to ensure that the concentration of “free” molecule solution as well that of the 
liposome encapsulated solution were comparable. PantSH is used to illustrate how this was 
done. First, a standard curve of PantSH was constructed by preparing series of PantSH 
solutions varying in concentration from 7 to 1000 mM and then measuring the fluorescence 
intensity of each of these solutions (Figure 3-3). A linear curve fit was performed on the data 
points using SigmaPlot® 14.0 software and the equation of the line was then used to 
determine the concentration of PantSH in a given liposomal preparation. 
 
Figure 3-3: Standard curve of [PantSH] as a function of CPM fluorescence intensity. Each data point 
represents the average of three replicates and the error bars indicated the standard deviations (n = 3 ± standard 
deviations). Linear curve fit gave the equation y= -898.179 + 49.087x (R² = 0.992). 
PantSH-loaded liposomes were prepared as described in Chapter 2. A fresh solution of 1 mM 
PantSH was also prepared. Equal volumes of the two preparations were transferred to a black 
96 well plate, 10 μM CPM was added to each and the fluorescence intensity was measured. 
Water was used as a reference since all the solutions (as well as the liposomal suspensions) 
were prepared in water.  Comparison of the fluorescence signal of the “free” PantSH and the 
liposome encapsulated PantSH to the reference solution show that both preparations emit 
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strong fluorescence signals (Figure 3-4). However, the fluorescence emission of the 1 mM 
PantSH solution is significantly higher than that of liposome-encapsulated PantSH solution.  
 
Figure 3-4: Fluorescence signal of "free" PantSH, as well as liposome-encapsulated PantSH solution.  
Water was used as a reference for measuring fluorescence intensity of CPM-PantSH adducts. Each data point 
represents an average of three technical repeats and the errors represent the standard deviations (i.e.: n = 3 ± 
standard deviations). Student’s t-test (paired distribution, * p < 0.05, *** p < 0.001). 
We proceeded to calculate the PantSH concentration in liposomes using the standard curve 
shown in Figure 3-3. The calculated concentration estimates the PantSH concentration in the 
liposomes to be 962.335 ± 60.7 μM (equation 1b). When considering the error this falls within 
a range close to 1 mM, which is the original concentration used to prepare the liposomes. The 
PantSH concentration of the 1 mM used to perform the “free” diffusion measurements was 
recalculated from the standard curve as a quality control measure. The calculation shows that 
the concentration is slight overestimated which in turn suggests that the accuracy of the 
standard curve could be improved (equation 2b). Unfortunately, despite several attempts, the 
standard curve could not be reconstructed to levels of accuracy beyond the one in Figure 3-3 
Therefore, we proceeded to calculate the encapsulation efficiency with PantSH concentrations 
of “free” PantSH and liposome-encapsulated PantSH determined from the standard curve. 
The encapsulation efficiency was calculated to be 92.43% for PantSH.  
3.1.1.1 Liposomal encapsulation efficiency 




PantSH-Liposome signal = 46340 ± 2082.411 Fluorescence units………………………….1(a) 
Therefore, 
[PantSH] in the liposome = (46340 + 898.179)/ 49.087 = 962.335 ± 60.7 μM……………..1(b) 
And,  
1 mM PantSH signal = 50206.33 ± 1037.791 Fluorescence units…………………………...2(a) 
“Free” [PantSH] = (50206.33 + 898. 179)/ 49.087 = 1 041.10 ± 39.51 μM………………….2(b) 
 
The encapsulation efficiency = (962. 335/ 1041.10) × 100 = 92.43 % ………………………3 
 
The encapsulation efficiency was also calculated for the thiol molecules used in the study and 
found to be above 90% in all cases (results not shown).  Since the difference between the 
encapsulated and “free” molecule solution was consistently below 10 % for the liposomal 
preparations tested, and the molecule loaded liposomes produced a fluorescence signal with 
comparable strength to the “free” molecule solution, the difference was considered small 
enough not to influence the data analysis. We concluded to proceed with the data processing 
described in Figure 3-2 for reporting the potential membrane permeability of the molecule of 
interest. 
 P-PantSH permeates the eukaryotic model membrane but not the bacterial 
membrane model 
The membrane permeability measurements of P-PantSH, its non-phosphorylated counterpart 
PantSH (Figure 3-1, 2), the representative of its cysteamine moiety H-SNAC (Figure 3-1, 3), 
as well as dePCoA and CoA were performed to determine the structure-permeability 
relationship that may exist for these molecules. Glutathione (GSH) is also a low molecular 
weight thiol, and protein transporters dedicated to its membrane translocation have been 
identified168. Therefore, this molecule is less likely to permeate cells by passive diffusion and 
for this reason it was used as a reference in the permeability measurements. The relative 
liposomal diffusion of GSH was set as a “permeability threshold” (indicated by the dotted lines, 
Figure 3-5) for both the eukaryotic and bacterial model membranes. Therefore, all molecules 
for which the liposomal diffusion was above this value was considered to have a membrane 
permeability exceeding that of GSH (i.e. they are relatively membrane permeable), and those 
below this value were considered to have a permeability below that of GSH (i.e. they are 
relatively membrane impermeable). 
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The “free” and liposomal diffusion rates were determined using the CPM-based fluorescence 
assay according to the strategy described in Figure 3-2. The results show that PantSH and H-
SNAC have the highest free diffusion rates and dePCoA and CoA have the lowest (Figure 3-5 
A and B). The molecular weight of CoA and dePCoA is almost six times that of H-SNAC, and 
these molecules also have an adenylyl group which gives them a “bulky” molecular geometry. 
Therefore, the observed diffusion rates are consistent with the principle that smaller molecules 
diffuse over distances relatively faster than larger molecules.  
The liposomal diffusion rates were measurably higher in POPC-Chol liposome than in the 
POPE-POPG-CL liposomes, which suggests that the eukaryotic model membrane is generally 
more permeable towards these molecules than the bacterial model. Nonetheless, comparison 
of the relative liposomal diffusion of the molecules to the permeability threshold show that P-
PantSH can likely permeate the eukaryotic model but not the bacterial membrane model, and 
that no other molecule can permeate either membrane model by passive diffusion. However, 
due to low free diffusion rates, dePCoA and CoA have much larger signal-to-noise- ratio. 
Therefore, more experimental repeats would be beneficial for confirming that the apparent 
permeability is indeed a true result. Nonetheless, the observed permeability of P-PantSH in 
the eukaryotic model is consistent with previous findings and validates our membrane model 




Figure 3-5: Membrane permeability profiles of P-PantSH, CoA and other thiol intermediates. “Free” and 
liposome-loaded diffusion rates (panels A and B) was used to determine the relative permeability (relative liposomal 
diffusion) of the thiol-containing molecules (panels C and D). This was done for both the eukaryotic (panels A and 
C) and bacterial (panels B and D) membrane models.  GSH was used as a reference and its relative liposomal 
diffusion was set as a permeability threshold indicated by a dotted line. For panels A and B, bar height indicates 
the average value from two experiments, with the error indicating the range/2. For panels C and D, bar height 
indicates the average value from the lowest and highest possible ratios, with the error indicating the upper limit. 
We next proceeded to investigate the membrane permeability of analogues of P-PantSH in 
which the cysteamine moiety was either completely absent (Figure 3-1, 4 & 5), or modified in 
such a manner that the terminal thiol was replaced with an alkyl or phenyl group (Figure 3-1, 
6 & 7). These compounds were studied to determine if the cysteamine moiety (and its thiol 
group in particular) contributes to the permeability of P-PantSH. For these compounds the 
ALP-Malachite green assay described in section 3.2.1 was used to determine the “free” and 
liposomal diffusion rates across both membrane models. Glucose-6-phosphate (G6P) was 
used as a reference because like GSH, protein transporters for its membrane translocation 
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have been identified and was therefore expected that is would not efficiently cross biological 
membranes by passive diffusion156. 
The results show that the outcome of the ALP-based assay is dependent on several factors, 
and therefore likely suffers from low reproducibility. Specifically, P-PantSH and P-PantOH 
were found to have the highest “free” diffusion rates in the first set of experiments (performed 
to study the permeability of the eukaryotic membrane model), but interestingly G6P had the 
highest “free” diffusion in the second set of experiments (for the study of the permeability of 
the bacterial membrane model) (Figure 3-6 A & B, respectively). Comparing the actual values 
obtained for the “free” diffusion rate of G6P, it was found to be ~6-fold higher in the second 
experiment. This large difference is likely because two different batches of ALP were used in 
each case. Since the amount of inorganic phosphate produced from cleaving a 
phosphorylated compound with ALP is used to determine the diffusion rate of the molecules 
of interest, the big difference suggests that variations in ALP activity may affect the observed 
diffusion rate.  
Although we did not see the same large variations in the “free” diffusion rates of the other 
compounds tested, the variation in the results obtained for G6P raises concerns about the 
validity of the data obtained for the other compounds. This can further be illustrated by the 
comparison of the obtained for P-PantSH, which indicate that this molecule cannot permeate 
POPC-Chol by passive diffusion when using the ALP assay (Figure 3-6 C), while the CPM 
assay used to obtain the data shown in Figure 3-5 indicated that it can. Overall, the data 
obtained with the ALP assay—although it seems to indicate that several of the phosphorylated 
pantothenate analogues can cross the membranes unaided—should be interpreted with 
caution. It would be ideal to repeat these experiments using a standard ALP substrate such 
as p-nitrophenyl phosphate (pNPP) (Section 2.2.9.2) for comparison, and to confirm the 
activity of the enzyme. 
We next proceeded to investigate the membrane permeability of non-phosphorylated 
pantothenate analogues to find out if any structure-permeability relationships could be 
deduced with these molecules (Figure 3-7). The molecules tested were similar to those tested 
in the previous experiment, except that they the phosphate group (Figure 3-1, 8-11). 
PanCOOH was used as a reference, because like the previous reference molecules, it has 
dedicated membrane transporters and is therefore not expected to efficiently cross biological 
membranes by passive diffusion66,68,152. For these assays, the PanK enzyme reaction was 






Figure 3-6: Membrane permeability measurements of phosphorylated pantothenate analogues, including 
P-PantSH. “Free” and liposome-loaded diffusion rates (panels A and B) was used to determine the relative 
permeability (relative liposomal diffusion) of the phosphorylated molecules (panels C and D). This was done for 
both the eukaryotic (panels A and C) and bacterial (panels B and D) membrane models.  G6P was used as a 
reference and its relative liposomal diffusion was set as a permeability threshold indicated by a dotted line. For 
panels A and B, bar height indicates the average value from two experiments, with the error indicating the range/2. 
For panels C and D, bar height indicates the average value from the lowest and highest possible ratios, with the 
error indicating the upper limit. 
Comparison of the free diffusion rate of the pantothenate analogues show that these 
molecules have similar diffusion rates which is to be expected since they have similar structure 
and molecular size (Figure 3-7 A & B). In contrast to the thiol-containing molecules, the 
liposomal diffusion measurements suggest higher permeability of these compounds of the 
POPE-POPG-CL (bacterial model) membrane than the POPC-Chol (eukaryotic model) 
membrane. The results seemed to indicate that PantSH and PantOH permeate across the 
prokaryotic membrane model, and also to some extent the eukaryotic membrane model 
(Figure 3-7 C and D). However, that data obtained with PantSH again contradicts that obtained 
with CPM in the first experiment (Figure 3-5), which indicated that PantSH does not permeate 
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either membrane. This result raised question also about the reproducibility of this assay, and 
the need to include controls and references to ensure that the activity of the PanK used in the 
assay remains constant. 
 
Figure 3-7: Membrane permeability measurements of non-phosphorylated pantothenate analogues. “Free” 
and liposome-loaded diffusion rates (panels A and B) was used to determine the relative permeability (relative 
liposomal diffusion) of the non-phosphorylated molecules (panels C and D). This was done for both the eukaryotic 
(panels A and C) and bacterial (panels B and D) membrane models.  PanCOOH was used as a reference and its 
relative liposomal diffusion was set as a permeability threshold indicated by a dotted line. For panels A and B, bar 
height indicates the average value from two experiments, with the error indicating the range/2. For panels C and 
D, bar height indicates the average value from the lowest and highest possible ratios, with the error indicating the 
upper limit. 
Taken together, these results obtained with the CPM assay show that P-PantSH can permeate 
eukaryotic but not bacterial membrane models by passive diffusion. The observed membrane 
impermeability of PantSH and H-SNAC in turn suggests that the phosphorylated pantoyl 
moiety is important for membrane translocation of P-PantSH. However, the indirect 
determination of the diffusion rates by using the ALP-Malachite green assay as well as the 
PanK-coupled enzyme assay produced data that was not reproducible in comparison to those 
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obtained with the CPM-based assay, making it difficult to obtain meaningful insight regarding 
structure-permeability relationships. 
In spite of this rather disappointing outcome, the data—when taken together—does seem to 
indicate that the permeability of a molecule of interest seem to be more dependent on the 
composition of the membrane, than on its own structure. This conclusion is made based on 
the large differences in the results obtained for the two membrane models, even when all other 
variables are expected to be similar between the two systems. Based on this outcome, we 
decided to investigate the impact that P-PantSH and PantOH has on membrane fluidity under 
various conditions. 
 Membrane interaction studies 
The next objective of the study was to find out whether or not the pantothenate analogues 
interacted with the membrane, and if there was any correlation between the membrane fluidity 
and such an interaction. For these studies PantOH was used because the findings from the 
membrane permeability studies suggested that this molecule most likely permeates both the 
eukaryotic and bacterial membrane models. In addition, the impact of P-PantSH on a 
membrane was also investigated, but only in the context of the eukaryotic membrane model, 
as this was the only system that showed some permeability to this molecule. 
An indicator of the interaction of either of these compounds with the membrane would be 
changes in membrane fluidity in the presence of the analogue. Liposomes were therefore 
prepared as was done in the previous experiment, except that reference liposomes were also 
prepared with only water loaded in the intraliposomal cavity. The fluidity was analyzed for 
liposomes suspended in water, as well as in a buffered environment. The buffered 
environment was introduced to investigate the effect of the pH on membrane fluidity, 
specifically as charged lipids like phosphatidylglycerol and cardiolipin are pH-sensitive and 
may therefore cause changes in fluidity as a response to changes in pH of their immediate 
environment. Therefore, two different solutions of 10 mM Tris-HCl were prepared at pH 7 and 
pH 8 to represent neutral and alkaline conditions respectively, and a solution of 10 mM MES-
HCl at pH 6 was prepared to represent an acidic environment. The selection of 10 mM ionic 
strength of the buffers falls within the range generally used for liposomal studies involving 
investigation of fluidity159,163. 
Artificial membranes like those represented by liposomes can assume three general phases 
based on the phospholipid composition thereof. These phases can in turn be used to describe 
membrane fluidity26. Membranes made exclusively of saturated phospholipids, especially 
those of cylindrical geometry like phosphatidylcholine, tend to be “gel-like” and these 
membranes are described as ordered or rigid. Introducing cholesterol to such membranes has 
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a fluidizing effect, however since cholesterol binds in an asymmetric manner, the membrane 
becomes unevenly thick in certain regions and is therefore described as liquid-crystalline or 
liquid-ordered membrane. Unsaturated fatty acyl chains, especially in phospholipids with 
conical geometry produces membranes of much higher fluidity than the two described above. 
Such lipids have low transition temperatures (Tm), and produce membranes described as 
liquid-liquid or liquid-disordered. 
Membrane fluidity was analyzed using Prodan – a membrane binding fluorophore that 
produces has an excitation maximum (λem) of 515 nm in water162. Prodan is loosely anchored 
to the bilayer and locates closer to the aqueous phase of the bilayer (Figure 3-8). This 
molecule experiences dipolar relaxation in a lipidic environment as a result of water molecules 
located at the level of the glycerol backbone where the fluorophore binds163,164. The dipolar 
relaxation results in a spectral shift which provides useful information about the membrane 
phase state, which in turn describes fluidity. 
 
Figure 3-8: Principle of Prodan-based membrane fluidity determination. Rigid membranes have less, and 
more fluid membrane have relatively more, water molecules moving at the aqueous interface and area surrounding 
the glycerol backbone. Prodan is sensitive to this water movement and its emission spectrum can provide 
information about the membrane based on this property. A prodan emission peak at 440 nm is characteristic of a 
“gel-like” ordered membrane phase, and an emission peak at 480 nm is characteristic of a liquid-disordered 
membrane phase.   
Generalized polarization (GP) is a method developed to quantitatively analyze the difference 
in Prodan emission spectra169. It is sensitive to the properties of the membrane and may allow 
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determination and quantification of these membrane phase states and in so doing describe 
the degree of fluidity of the membrane.  
GP can be defined as follows: 
GP = IB – IR/ IB + IR         …..1 
Where, IB = Fluorescence intensity at λ440 and IR = Fluorescence intensity at λ480. 
The GP values are restricted between 1 and -1. The higher the membrane associated water 
movement, the closer the value is to -1, and the lower the water movement the closer the 
value is to 1. A “gel-like” membrane is indicated by ordered phase, it has restricted water 
movement and the GP value in that case would be closer to 1. On the other hand, liquid-
ordered (liquid-crystalline) as well as liquid-disordered (liquid-liquid) phases have higher 
membrane associated water movement and would therefore result in GP values close to -1. 
3.2.4.1 Both P-PantSH and PantOH interact with the eukaryotic membrane model 
Prodan emission spectra were recorded for control liposomes (containing no compound), as 
well as for POPC-Chol liposomes loaded with either P-PantSH or PantOH. The Prodan 
emission spectra were recorded in a non-buffered environment, as well as at pH 6, 7 and 8 
respectively. All four sets of spectra have a distinct emission peak at 440 nm which suggests 
the presence of relatively ordered particles for all liposomes tested. This is supported by the 
negative control sample, which contains no liposomes but only Prodan and water, where no 
peak at 440 nm is observed (spectrum not shown). Since the emission at 480 nm also gives 
valuable information about membrane fluidity, the slopes of the change in emission from 440 
nm to 480 nm were evaluated to determine the influence that the presence of P-PantSH or 
PantOH has on membrane fluidity. The results indicate that change is larger in P-PantSH 
loaded liposomes (Figure 3-9 A) compared to that of the control liposomes and PantOH-




Figure 3-9: Membrane fluidity of POPC-Chol in the presence of P-PantSH and PantOH. Prodan emission 
spectra of control liposome, P-PantSH-, and PantOH-loaded liposomes were recorded in water (A), pH 6 (B), pH 
7 (C) and pH 8 (D), respectively. The GP values were calculated from these spectra and used to evaluate the 
membrane fluidity for the three liposomal preparations under the different conditions (E).The experiment was 
performed in triplicate; the bars show the average value and the errors show the standard deviation.  
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On the other hand, the PantOH-loaded liposome has a higher emission at 480 nm which 
results in a flat slope relative to control and P-PantOH-loaded liposomes at pH 6 and 8 (Figure 
3-9 B & D). This is indicative of a membrane “fluidizing” effect by this molecule. All the 
liposomal preparation had similar spectra at pH 7 which suggests similar membrane phases 
for all three at this pH (Figure 3-9 C).  
The GP values were calculated and used to compare membrane fluidity for all three liposomal 
preparations under all four conditions (Figure 3-9 D). The GP of the empty POPC-Chol 
liposome suspended in water is 0.43 ± 0.13 which is indicative of a liquid-crystalline phase as 
is expected for a membrane of this phospholipid composition. This GP value drops to ~0.3 
under buffered conditions which implies the influence of ionic strength on fluidity of this 
membrane model. P-PantSH-loaded liposomes have a GP value of ~0.4 under all four 
conditions. This implies a membrane “ordering” effect by P-PantSH, especially under buffered 
conditions. However, this effect is not pH-dependent since the GP values are similar for all 
four conditions. Conversely, PantOH-loaded liposomes of 0.26 ± 0.047 water, and this slightly 
drops to 0.19 ± 0.005 and 0.18 ± 0.003 at pH 6 and 8, respectively, suggesting “fluidizing” 
effect by PantOH at these pH levels. This dependence on pH is further highlighted by the 
membrane “ordering” effect indicated by a slightly higher GP value of 0.31 ± 0.006 at pH 7.  
3.2.4.2 PantOH has minimal interaction with the bacterial membrane model 
Prodan spectra were also recorded for control liposomes and PantOH-loaded liposomes for 
the bacterial membrane model. Evaluation of the curves of the spectra obtained in water as 
well as at pH 6, 7 and 8, show similar slopes which suggest minimal change in fluidity as a 
result of the presence of PantOH (Figure 3-10 A-C). Evaluation of the GP values show that 
both the control as well as PantOH-loaded liposomes have GP values of 0.13 and 0.12, 
respectively   (Figure 3-10 D) which is lower than the POPC-Chol liposomes which had an 
average GP value of 0.4 ± 0.13 (Figure 3-9 D). This suggests a higher degree of fluidity in 
POPE-POPG-CL than POPC-Chol membranes. This can be attributed to a difference in 
phospholipid head groups since all the phospholipids have the same fatty acyl chains.  
On the other hand, a slightly lower value of 0.12 ± 0.0004 for PantOH-loaded liposomes 
relative to 0.13 ± 0.001 for control POPE-POPG-CL in water was observed. This is indicative 
of “fluidizing” effect by PantOH which is consistent with the observation for POPC-Chol fluidity 
analysis (Figure 3-10 D). Nonetheless, these PantOH-induced effects were small, suggesting 
that the interaction with the membrane is low or minimal. As result, subsequent fluidity 






Figure 3-10: Membrane fluidity of POPE-POPG-CL in the presence of PantOH. Prodan emission spectra of 
control as well as PantOH-loaded liposomes were recorded in water (A), pH 6 (B), pH 7 (C) and pH 8 (D), 
respectively. The GP values were calculated from these spectra and used to evaluate the membrane fluidity for 
the three liposomal preparations under the different conditions (E). The experiment was performed in triplicate; the 




3.2.4.3 Ionic strength and composition do not influence interaction of P-PantSH and 
PantOH with the eukaryotic model membrane  
Following the observation that the fluidity of POPC-Chol is influenced by ionic strength, we 
decided to investigate the influence of ionic composition on membrane fluidity, and whether 
or not the ions affect the interaction of pantothenate analogues with the membrane. 
Potassium, sodium and calcium ions (K⁺, Na⁺ and Ca²⁺, respectively) are electrochemical 
gradient components and are important for the membrane translocation of some 
molecules170,171. For this reason, their effects on membrane fluidity were evaluated. Control, 
P-PantSH- and PantOH-loaded liposomes were prepared as previously described.  
Membrane fluidity of the liposomal preparations was determined by the recording prodan 
spectra in water as well as in the presence of KCl, NaCl and CaCl₂ (1 mM of each, Figure 
3-11). Though sufficient to perturb membranes, 2 mM CaCl₂ was shown to prime liposomal 
particles start to aggregate at this concentration, and for this reason we elected to use a lower 
concentration, that would presumably affect fluidity without causing aggregation of liposomal 
particles172. The GP values were calculated from the spectra and the effect of the ions 
evaluated. The GP value of the control POPC-Chol liposomes was used as a reference 
(indicated by the dotted line) for comparison.  There is a slight increase in GP in the presence 
of Ca²⁺, suggesting membrane “ordering” effect of this ion compared to control liposomes. P-
PantSH also has a membrane “ordering” effect which is consistent with previous findings. 
However, the presence of ions does not seem to influence this effect. PantOH also has 
membrane disordering effect which is also consistent with previous findings. Nonetheless, a 
slight increase in GP value was observed for this liposomal preparation in the presence of the 
ions. This increase may not be large enough to make any conclusions regarding the effects of 
ions on interaction of PantOH with the POPC-Chol membrane, however it does justify further 




Figure 3-11: Influence of ionic composition on membrane fluidity of POPC-Chol liposomes.  Membrane 
fluidity of control, P-PantSH- and PantOH-loaded liposomes was evaluated in the presence of 1 mM of either KCl, 
NaCl and CaCl₂ to evaluate the effect of K⁺, Na⁺ and Ca²⁺ on the fluidity. The experiment was performed in triplicate; 
the bars show the average value and the errors show the standard deviation. 
3.2.4.4 Membrane fluidity modulates the interaction of pantothenate analogues with the 
membrane 
It is presumed that the effect of P-PantSH and PantOH on membrane fluidity are a result of 
interaction of these molecules with the membrane. Therefore, we wanted to identify the 
determinants of this interaction. Was it the chemical identity of the molecule of interest, a 
specific phospholipid composition, or are the interactions modulated by the fluidity of the 
membrane? To answer these questions, variations of the eukaryotic membrane models that 
differed in the degree of fluidity were prepared. Unlike POPC, dipalmitoylphosphatidylcholine 
(DPPC) has two saturated fatty acyl chains.  Consequently, a membrane model of higher 
rigidity was prepared with DPPC phospholipids. Liposomes made up of POPC and DPPC in 
a 1:1 ratio were prepared to evaluate membrane fluidity in the absence of cholesterol.  
Furthermore, since findings from membrane permeability studies suggest importance of the 
phosphorylated pantoyl moiety for P-PantSH permeability, we wanted to find out if there was 
any correlation between this factor and membrane fluidity. We also wanted to determine the 
reason for differing effects on membrane fluidity upon addition of P-PantSH and PantOH: was 
the phosphate group or cysteamine moiety responsible for the difference? In order to achieve 
these objectives, the effects of P-PantSH and PantOH on membrane fluidity were evaluated. 
In addition, PantSH, P-PantOH, PanCOOH and P-PanCOOH were also included in this 
experiment as all these compounds contain a pantoyl moiety, and by using the phosphorylated 
and unphosphorylated counterparts of all the analogues we could investigate the importance 
of the 4’-phosphate group on fluidity. 
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Liposomes with no pantothenate analogue loaded in the intraliposomal cavity were prepared 
as controls (reference membranes) for comparison. Liposomes loaded with one of each of the 
6 pantothenate analogues mentioned above was prepared for all three lipid compositions. The 
liposomes were prepared in 10 mM Tris-HCl, pH 7 since the fluidity was found to be influenced 
by ionic strength. Prodan spectra were recorded for all preparations and GP values calculated 
to determine fluidity. 
Evaluation of the spectral overlays show relatively flat spectra for POPC-Chol and POPC-
DPPC (Figure 3-12 A & B, respectively), and steep slopes as a result of emission at 440 nm 
for the DPPC membrane. These in turn suggest that DPPC membranes are much more rigid 
than POPC-Chol and POPC-DPPC membranes. This is further confirmed by GP values of 
0.06 ± 0.012 and 0.02 ± 0.01for POPC-Chol and POPC-DPPC control liposomes, respectively, 
which is lower than GP values of DPPC control liposomes of 0.38 ± 0.012. 
 
 
Figure 3-12: Interaction of pantothenate analogues with the membrane is dependent on the degree of 
membrane fluidity. POPC-Chol (A), POPC-DPPC (B) and DPPC (C) represent variations of the eukaryotic 
membrane model which differ in the degree of fluidity. These were prepared with either P-PantSH, P-PanCOOH 
and P-PantOH or their non-phosphorylated form loaded in the intraliposomal cavity. The Prodan spectra were then 
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recorded for all three membrane models and the GP values evaluated (D) to compare the effects of the 
pantothenate analogues on fluidity. 
Evaluation of effect of pantothenate analogues on membrane fluidity suggests a membrane 
“ordering” effect by P-PantSH, in POPC-Chol and POPC-DPPC membranes. P-PanCOOH 
also had membrane “ordering” effects in POPC-DPPC membrane. These pantothenate 
analogue induced changes in membrane fluidity were greater in a membrane model of 
relatively higher fluidity than the rest. Furthermore, there were marginal effects in the 
membrane model of lower fluidity. This is in turn suggests a requirement for a certain degree 
of fluidity for pantothenate analogue interaction.  
3.3 Discussion 
 Direct molecule quantification improves reproducibility in liposome-based 
assays 
Liposomes were used as an in vitro membrane system to perform this study as liposomes are 
versatile and easy to prepare54,57,173. However, these particles are infamous for poor 
reproducibility and there have been attempts to create alternative membrane models with 
better reproducibility136,174. However, the preparation of these alternatives is cumbersome and 
are therefore also not very attractive options. As reproducibility is a known challenge, this 
study went to lengths to optimize the encapsulation efficiency of the liposomes and a reference 
molecule was also included with all the measurements performed in an effort to circumvent 
these issues (Chapter 2). We were able to produce meaningful permeability data for low 
molecular weight thiols associated with CoA using this liposome-based system as a sensitive 
fluorophore that enables direct measurement of a molecule of interest minimises variability 
and can improve reproducibility despite the liposomal system. In contrast, the indirect 
measurement assays used for phosphorylated and non-phosphorylated analogues had poor 
reproducibility and as a result, no definitive conclusions were made from the data obtained for 
these molecules.  
 The phosphorylated pantoyl moiety may be important for membrane 
translocation 
Membrane permeability measurements went on to show that P-PantSH permeates the 
eukaryotic membrane model but not the bacterial model. Charge repulsion between the 
membrane surface and phosphate group of P-PantSH may play a role in the inability of this 
molecule to permeate bacterial membranes given that POPG and CL give the liposomal 
membrane a slightly negative charge since these two lipids both are negatively 
charged26,166,167. Additionally, this is supported by the higher relative liposomal diffusion of 
PantSH in this membrane model which suggests that the non-phosphorylated form may cross 
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the bacterial membranes more efficiently but not necessarily fast enough to support growth. 
On the other hand, the poor permeability demonstrated for PantSH and H-SNAC in the 
eukaryotic membrane model suggests the importance of the phosphorylated pantoyl moiety 
in membrane translocation of P-PantSH. Unfortunately, such a structure correlation could not 
be established with other phosphorylated pantothenate analogues.  
 Membrane fluidity modulates P-PantSH-membrane interactions in the 
eukaryotic membrane model 
We then went on to show that the presence of either P-PantSH or PantOH in the membrane 
alters the fluidity which suggests interaction of these molecules with the membrane in 
eukaryotic membrane models. The PantOH interaction is pH dependent as illustrated by the 
different effects on fluidity at different pH levels. This could be attributed to the dissociation 
properties of this molecule under different pH conditions. For instance PantOH is known to 
have hydration effects when applied ectopically175. The skin has a pH of ≈ 5.5176, and we 
showed a PantOH induced increase in membrane fluidity at pH 6. This phenomenon may 
therefore be explained as follows: the solubility-diffusion theory describes transient aqueous 
pockets that exist at the surface of the membrane as well as vicinity of the glycerol backbone. 
The theory further states that solutes dissolve into these pockets to permeate the membrane. 
Therefore, the “fluidizing” effect of PantOH suggests that this molecule is able to recruit more 
of the aqueous pockets to the membrane surface. It would therefore be interesting to find out 
if co-administration of other small molecules with PantOH improves their permeability as a 
result of this effect.  
The permeability of PantOH across mammalian cells is assumed and though we could not 
demonstrate this, the liposomal diffusion rate of this molecule in our eukaryotic system 
suggests the ability of the molecule to cross the in vitro membrane with some efficiency. And 
since the two molecules produced similar fluidity effects at pH 7, it possible that at 
physiological pH these two molecules are likely to interact or translocate over the membrane 
in a similar manner. Which we propose is by a mechanism illustrated in Figure 3-13 which is 




Figure 3-13: Proposed mechanism of P-PantSH permeation. A) Structure of P-PantSH, showing the polar (in 
blue circle) and amphiphilic (in orange) moieties. B) Proposed mechanism whereby P-PantSH could pass through 
a lipid bilayer. The molecule inserts itself in one leaflet in the same orientation as a phospholipid, after which it 
undergoes a flip-flop exchange to the inner leaflet. From here, it is released to the cytosol. Adapted from 177. 
Our findings also show that membrane fluidity modulates the interaction of P-PantSH with the 
membrane, with the interaction becoming more pronounced in membrane compositions of 
higher fluidity. Furthermore, P-PanCOOH membrane interaction, as indicated by a change in 
the fluidity, was also observed in the membrane model of higher fluidity. This is line with the 
view that a phosphorylated pantoyl moiety is important for membrane translocation of P-
PantSH. The membrane fluidity analysis also shows that pH and ionic strength influence 
membrane fluidity, though not to the extent that it alters the pantothenate analogue induced 
effects, and perhaps altering the membrane permeability assay to include these factors may 
yield better outcomes. 
3.4 Materials and methods 
 Preparation lipid dry films 
Lipid stocks of 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphophatidylcholine (POPC), 1-
palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine (POPE), 1-palmitoyl-2-oleoyl-sn-
glycero-3-phosphoglycerol (POPG) and cardiolipin (CL) and cholesterol were prepared by 
weighing out the dry lipid powder and dissolving it in chloroform to a concentration of 10 mg/mL 
for each compound. To prepare the eukaryotic membrane model, POPC and cholesterol were 
mixed together in a 9:1 (w/w) ratio to a final volume of 1 mL per preparation. The bacterial 
membrane model was prepared by mixing POPE, POPG and CL in a 7:2:1 ratio (w/w) also to 
a final volume of 1 mL per preparation. The lipid mixtures were transferred to round bottom 
flasks after which the organic solvent was removed in vacuo. Residual solvent was removed 
under high vacuum for a period of 12 hours to produce dry lipid films. 
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 Preparation of liposomes loaded with thiolated molecules 
The dry lipid films of eukaryotic or bacterial membrane model mixtures were rehydrated with 
1 mM of either GSH, PPantSH, PantSH, dePCoA, CoA or H-SNAC target metabolite, each 
with 1.5 mM TCEP as a reducing agent.  Following rehydration with a solution of GSH and 
reducing agent, the lipid suspension was incubated at 60˚C for 20 minutes with constant 
vortexing at 5-minute intervals. The suspension was then flash-frozen in liquid nitrogen (~ 80 
°Ϲ) and allowed to thaw at room temperature (~ 22 ˚C). The freeze-thaw cycle was repeated 
five times to promote formation of unilamellar vesicles. The suspension was then subjected to 
20 extrusion passages to form SUVs (liposomes) of uniform size using the Avanti™ mini-
extruder fitted with two 800 nm polycarbonate filters (Whatman). Excess metabolite was 
removed by size exclusion chromatography in a Sephadex-G75 column prepared in-house. 
To prepare the column, 2 g of Sephadex-G75 beads was weighed out and hydrated with MilliQ 
water. The slurry was allowed to stand at room temperature for 1 hour for full hydration of the 
beads. The excess buffer was decanted out and the slurry was transferred to a 5 mL syringe 
column sealed with cotton wool. The column was then placed in a 15 mL centrifugal tube and 
the beads were packed by centrifugation at 3 000 g for 5 minutes in a benchtop swing bucket 
centrifuge. The flow through was then discarded and the extruded lipid suspension was then 
placed on the column bed. The thiol metabolite-loaded liposomes were then harvested by 
centrifugation at 1 000 g for 5 minutes in a swing bucket rotor. The purified liposome 
suspension was then collected in the flow through and stored at 4 °C until further use. 
 Preparation of pantothenate analogue-loaded liposomes 
POPC-Chol and POPE-POPG-CL liposomes respectively loaded with 5 mM of either 
PanCOOH, PantSH, N5-Pan, N-PE-Pan or PantOH were prepared as described in 3.3.1.1 for 
thiol molecule-loaded liposomes. 
 Preparation of phosphopantothenate analogue-loaded liposomes 
POPC-Chol and POPE-POPG-CL liposomes respectively loaded with 5 mM of either G6P, P-
PanCOOH, P-PantSH, P-N5-Pan, P-N-PE-Pan or P-PantOH were prepared as described in 
3.3.1.1 for thiol molecule-loaded liposomes. 
 Determination of membrane permeability of thiolated molecules by the CPM-
based fluorescence assay 
A 1 mM solution of either GSH, PPantSH, PantSH, dePCoA, CoA or H-SNAC was prepared 
to represent to determine the “free” metabolite diffusion rate. To each solution, 1.5 mM Tris-
2-Carboxyethylphosphine (TCEP) which is reducing agent, was added. Three dialysis 
membrane units were hydrated for 10 minutes in 3 ×10 mL beaker filled with 900 μL of MilliQ 
water. Following hydration, 200 μL of a respective solution was placed inside these dialysis 
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membrane units, and the diffusion rate were then monitored by collecting 20 μL aliquots of 
each dialysate at 0.5 hour intervals for 2.5 hours, such that the measurements were performed 
in triplicate. The aliquots were then transferred to a black 96 well plate to which 160 μL MilliQ 
water and 20 μL of 10 μM CPM were added. The plate was then incubated at room 
temperature for 30 minutes to allow formation of CPM-adducts. Following this, the 
fluorescence intensity of each aliquot was measured on the fluorimeter (TECAN spark 10M, 
Switzerland) at λex = 387 nm and λem = 465 nm. The liposomal diffusion rate was then 
determined by placing 3×200 μL of the lipid suspensions prepared in 3.4.2 in dialysis 
membrane units placed in 3×10 mL beakers. The diffusion rate was determined as described 
above for “free” metabolite diffusion. The fluorescence intensity values were then plotted 
against time intervals at which the aliquots were collected. The diffusion rates were then 
determined by calculating the slopes of respective plots. The liposomal diffusion rate was then 
normalized to the “free” metabolite diffusion rate to describe relative liposomal diffusion, where 
a value of 1 would indicate that the liposomal diffusion is equal to the free diffusion rate. The 
process was repeated for each respective metabolite. The relative permeability of GSH was a 
set as a reference for the membrane model in question.  
 Determination of membrane permeability Pantothenate analogues by the 
coupled enzyme (PanK-PK-LDH) assay  
A 5 mM solution of either PanCOOH, PantSH, N5-Pan, N-PE-Pan or PantOH was prepared 
to determine the “free” metabolite diffusion rate. Three dialysis membrane units were hydrated 
for 10 minutes in 3 ×10 mL beaker filled with 900 μL of MilliQ water. Following hydration, 200 
μL of a respective solution was placed inside these dialysis membrane units, and the diffusion 
rate were then monitored by collecting 20 μL aliquots of each dialysate at 0.5 hour intervals 
for 2.5 hours, such that the measurements were performed in triplicate. The liposomal diffusion 
rate was then determined by placing 3 × 200 μL of the lipid suspensions prepared in 3.4.3 in 
dialysis membrane units placed in 3 × 10 ml beakers. The diffusion was monitored by the 
same method as described above for “free” metabolite diffusion. All aliquots of 20 μL dialysate 
were transferred to a clear 96 well plate. A reaction mixture containing 1.5 mM ATP, 2 mM 
PEP, 0.5 mM NADH, EcPanK (2 μg/ 200 μL reaction), 2 U PK, 2 U LDH in a 50 mM Tris-HCl 
pH-7.4, 20 mM KCl, 20 mM MgCl₂. buffer was prepared. Following this, the presence of 
metabolite of interest in each aliquot was determined by adding 180 μL of the reaction mixture 
and monitoring change in absorbance at 340 nm to determine NADH consumption from each 
aliquot. The NADH consumption was then calculated from the resultant slopes for each 
aliquot.  The coupled enzyme assay is set up in such a manner that the NADH consumption 
rate corresponds to the amount of molecule of interest used as a substrate for the PanK 
reaction.  For this reason, the resultants NADH rates for each aliquot were plotted against the 
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time interval at which the aliquot was collected to represent the progression of diffusion of the 
metabolite of interest. The slopes of these plots were then used to calculate the diffusion rate 
of each of the metabolites included in the study. The relative permeability was calculated from 
the “free” metabolite and liposomal diffusion rates as described in 3.4.5. The relative 
permeability of PanCOOH was a set as a reference to determine “true” permeability across 
the membrane model in question.  
 Determination of membrane permeability of phosphorylated pantothenate 
analogues by the alkaline phosphatase (ALP) & malachite green assay 
A 5 mM solution of either G6P, P-PanCOOH, P-PantSH, P-N5-Pan, P-N-PEPan or P-PantOH 
was prepared to determine the “free” metabolite diffusion rate. Three dialysis membrane units 
were hydrated for 10 minutes in 3×10 mL beaker filled with 900 μL of MilliQ water. Following 
hydration, 200 μL of a respective solution was placed inside these dialysis membrane units, 
and the diffusion rate was then monitored by collecting 20 μL aliquots of each dialysate at 0.5 
hour intervals for 2.5 hours, such that the measurements were performed in triplicate. The 
liposomal diffusion rate was then determined by placing 3×200 μL of the lipid suspensions 
prepared in 3.4.4 in dialysis membrane units placed in 3 × 10 ml beakers. The diffusion was 
monitored by the same method described above for “free” metabolite diffusion. To determine 
the diffusion rate, a Malachite green solution consisting of 0.034% Malachite green, 3.4% 
Ethanol, 10 mM ammonium molybdate dissolved in up to 1 M HCL (HPLC grade, 99% Purity, 
Merck, Germany). A phosphate cleavage reaction was prepared by adding 4 mM NiCl₂, 50 
mM Tris-HCl, pH 7.6, 0.1 mM CaCl₂, BSA (2 mg/mL) and 5 U ALP to each 20 μL aliquot to a 
final volume of 100 μL. Each reaction mixture was incubated at 37 °C for 2.5 h to allow 
cleavage of the phosphorylated compound by malachite green assay. Following this, the 
enzyme was heat inactivated at 65 °C for 15 minutes. The reaction components were then 
removed by centrifugation at 13 000 g for 5 minutes. The supernatant from each aliquot was 
transferred to a 96 well plate. To determine the amount of phosphate in each aliquot, 50 μL of 
the malachite green solution was added was transferred to each well. The plate was allowed 
to stand at room temperature for 10 minutes for color development. The absorbance for each 
aliquot was measured at 625 nm and plotted against time to show the diffusion of each 
molecule of interest over time. The slopes of the resultant plots were then used to calculate 
the diffusion rate for each molecule of interest. Following this, the relative permeability was 
calculated as described in 3.4.5. The relative permeability of G6P was set as a reference to 
determine the “true” permeability across the membrane model. 
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 Prodan spectral recording and GP determination 
A 1 mM stock of Prodan was prepared in DMSO. Following this, 20 μL of the control 
POPC/Chol liposomal preparation was transferred to a black 96-well plate. The liposomes 
were diluted 10 × with 180 μL water. Prodan solution was then added to a final concentration 
of 10 μΜ (i.e. ~2 μL of the stock). The plate was then incubated at room temperature for 15 
minutes to allow incorporation of the dye into the membrane. The emission spectra were then 
recorded on the TECAN SPARK 10 M fluorimeter, at λₑₓ = 370 nm with the signal gain 
manually set to 50%. This procedure was repeated for control POPE/POPG/CL, as well as 
the P-PantSH and PantOH loaded liposomes. The procedure was repeated again, this time 
adding 1 mM of either Tris-HCl (pH 7.00), Tris-HCl (pH 8.00) or MES-HCl (pH 6.00) to each 
liposomal preparation. The spectra were collected at 25 °C for all liposomal preparations. Then 
finally, the general polarization (GP) value was calculated from each spectrum.  
 Investigation of fluidity of the eukaryotic membrane model 
2-palmitoyl-sn-glycero-3-phosphophatidylcholine (DPPC) lipid films were prepared as 
described in 3.4.1 for POPC-Chol and POPE-POPG-CL. Lipid films POPC: DPPC in a ratio of 
1:1 (w/w) were also prepared in the same way. The lipid films were either hydrated with MilliQ 
water – to represent control membranes, or with 5 mM P-PantSH or 5 mM PantOH. The 
Prodan spectra were recorded in 10 mM Tris-HCl, pH 7.4 for all membrane models in question. 
The measurements were performed as described in 3.4.8. 
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4 SLC25A16 transports P-PantSH in an ADP-dependent 
manner 
4.1 Introduction 
Mitochondrial carriers (MCs) are a superfamily of transporters classified as SLC25 (solute 
carrier family 25) in mammals178. All members of this family have a tripartite structure of 
tandemly repeating domains of at least 100 amino acid length179. A substantial amount of 
metabolic machinery is compartmentalized into mitochondrion. Therefore, MCs provide a link 
between organellar and cytoplasmic metabolic activity by catalyzing translocation of numerous 
solutes across the mitochondrial membranes. Despite the apparent structural similarity, MCs 
have functional diversity and transport a large variety of solutes that differ in size and chemical 
properties178,180,181. Therefore, the MCs can be further classified into subfamilies based on 
substrate specificity, mode of transport and kinetic properties. For example, some MCs 
exclusively transport negatively charged particles, some catalyze a 1:1 substrate exchange 
(antiport), some are uniporters, some are H⁺-compensated symporters, and some use a 
combination of these mechanisms to transport solutes. Some membrane transporters 
classified as MCs localize to other organelles such as the peroxisome and chloroplast178. 
At least three MCs associated with the transport of CoA have been identified in mammals. 
These include SLC25A16, SLC25A17 and SLC25A42. SLC25A16 was originally thought to 
be associated with Grave’s disease and was accordingly named Grave’s disease carrier 
protein. However, it was later shown that a missense mutation of this transporter leads to the 
reversal of CoA levels between the cytosol and mitochondrion suggesting its role in the 
maintenance of mitochondrial CoA pools178,182. Nonetheless, direct characterisation of this 
protein is yet to be performed. SLC25A16 is closely related to SLC25A42 and the latter is 
highly expressed in most mammalian tissues124 (Figure 4-1). A Homo sapiens isoform of 
SLC25A42 was characterized and found to function by a counter exchange mechanism in 
which uptake of one substrate requires efflux of another. It has the highest affinity towards 
adenosine 3',5’-diphosphate (PAP), with a Km value of 50 ± 7 μM. This transporter also has 
affinity towards dePCoA and CoA, with Km values of 64 ± 9 μM and 71 ± 10 μM, respectively. 
A missense mutation in the gene that encodes this protein causes mitochondrial myopathy 
associated with lactic acidosis and muscle weakness which highlights its importance in the 





Figure 4-1: Phylogenetic analysis of mammalian mitochondrial carriers. The analysis indicates that 
SLC25A16 and SLC25A42 clusters together (indicated by the yellow rectangle). This suggests functional homology 
between the two carriers. Adapted from Palmieri et al.178 
Unlike the other two, SLC25A17 localises to the peroxisome125. H. sapiens SLC25A17 has 
also been characterized and was also shown to function by a counter-exchange mechanism. 
Its transport affinity was determined to be 19 ± 3 μM for [14C] AMP/AMP exchange at 25 ⁰C. 
Amongst others, CoA and dePCoA were found to be competitive inhibitors of [14C] AMP 
uptake, with Ki values of 19.6 ± 3.8 μM and 14.4 ± 5.4 μM, respectively. This transporter also 
demonstrates affinity towards the flavin cofactors FAD and FMN, the adenosine nucleotides 
ADP and PAP, as well as folate and NAD⁺125.  
SLC25A42 exhibits high sequence homology towards carriers of ADP/ATP as well as ATP-
Mg/Pi, while SLC25A17 exhibits high sequence similarity towards other pyrimidine nucleotide 
carriers and the folate/NAD⁺ carrier. Therefore, the rationale for screening free CoA, acetyl-
CoA and dePCoA as substrates for these proteins was informed by its apparent homology 
towards nucleotide-recognizing carriers124,125.The observed affinity of these transporters 
towards CoA and dePCoA (3) is consequently attributed to the ability to recognize the adenylyl 
moiety (2) present in all these molecules (Figure 4-2).   
However, it would be interesting to find out if these MCs exhibit any affinity towards the P-
PantSH moiety (1), especially in SLC25A17 which shares sequence homology with a folate 
transporter. This is because both folate and PanCOOH are vitamin molecules, and the latter 
is a precursor of CoA and a structural analogue of P-PantSH. Furthermore, the probability of 
transport of these molecules was ruled out in SLC25A42 on the premise that CoA biosynthesis 
took place exclusively in the cytoplasm. However, we now know that enzymes involved in CoA 
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salvage, i.e. PANK2 and CoASy, localize to the mitochondrion118,122. This in turn suggests that 
any of the CoA precursors (PanCOOH, PantSH, P-PantSH or dePCoA) could potentially cross 
the mitochondrial membranes63, and transport by the MCs associated with CoA transport 
would be an effective way in which this would be achieved. 
 
Figure 4-2: Affinity of the MC towards a substrate depends on its ability to recognize either the P-PantSH 
(1) or adenylyl moiety (2). Among the molecules identified as substrates for SLC25A42 and SLC25A16 is dePCoA 
(3) which has both the adenylyl and P-PantSH moieties. ATP, ADP and AMP are examples of molecules containing 
the adenylyl moiety and that are common substrates of some transporters in the SLC25 class. 
Kinetic characterisation of SLC25A42 and SLC25A17 was previously done using in vitro 
homo-exchange assays using proteoliposomes reconstituted with the transporter in question. 
The proteoliposome was preloaded with one component and then the uptake of another was 
measured124,125. For these assays, the intraliposomal component was a non-labelled 
compound, with the radiolabeled form being placed outside the liposome so that the uptake 
could be determined by monitoring the increase of radioactivity inside the liposome.  
Performing transport assays in this manner requires access to the radiolabeled versions of 
the compound of interest. A wide variety of radiolabeled compounds are commercially 
available; however if a required compound is not available, it can be synthesized in house if 
there is capacity to do so. There are financial implications in either case, but the major 
drawback of the latter is the time spent on chemical synthesis. Therefore, availability of a 
radiolabeled compound can limit the size and diversity of sample set for transport screening. 
It may therefore be useful to have an alternative method that does not require the use of 
radiolabeled compounds to study the transport kinetics of a membrane protein. The 
discontinuous liposomal assay for membrane permeability measurement described in chapter 
Stellenbosch University https://scholar.sun.ac.za
91 
2 is one such alternative. The assay was designed in such a manner that detection methods 
can be changed as required to accommodate molecules with a diversity of chemical 
structures.  
Therefore, the main aim of this part of the study was to investigate the transport kinetics of 
SLC25A16 using the discontinuous liposomal assay for permeability measurements. 
SLC25A16 is a particularly interesting candidate to characterize because no direct kinetic 
characterisation of this transporter has been performed to date. Furthermore, of the three 
transporters, it is the only one for which there is evidence directly linking it to CoA levels in the 
mitochondrion. Based on previous research, we have proposed a key regulatory role of P-
PantSH in the maintenance of subcellular CoA pools of which the mitochondrion is one. 
Therefore, the affinity of SLC25A16 towards this molecule was investigated. Moreover, since 
this transporter exhibits sequence similarity towards SLC25A42, dePCoA and the adenosine 
nucleotides ATP and ADP were also included. The finding that CoASy (which uses dePCoA 
as substrate) to the mitochondrion provides further rationalization for inclusion of dePCoA in 
the sample set. PantSH, which is a precursor of CoA salvage, was also included such that all 
potential precursors of CoA in the mitochondrion were screened. Taken together, this part of 
the study provides the first insights into the substrate preference of the human SLC25A16 
carrier. 
4.2 Results 
4.2.1 Expression, purification and functional reconstitution of SCL25A16 
Identification and characterization of a solute carrier requires identification of suitable 
substrates178. The most successful strategies for this include gene expression and purification 
of recombinant proteins and reconstitution into liposomes followed by direct protein assays184. 
This strategy appears simple but can fail for numerous reasons. Some of these reasons 
include difficulties experience with expression and subsequent purification of the protein, 
mainly because these proteins are often found in inclusion bodies in the cytoplasm of E. coli 
cells due to their foreign nature as well as the need to be included in membranes. This can 
lead to extensive efforts to resolubilize and refold the protein before it can be incorporated in 
proteoliposomes. Therefore, the first objective of the study was to express and purify the 
SLC25A16 protein to apparent homogeneity.  
The gene construct encoding H. sapiens SLC25A16 cloned into a high copy expression vector 
(pRUN) was expressed in E. coli C41 (DE3) cells. This cell line was preferred over BL21(DE3) 
cells as mitochondrial carrier proteins tend to become toxic towards this strain, while the 
C41(DE3) strain is engineered to be more tolerant of such potentially toxic proteins 184. Starter 
cultures were prepared by inoculating 4×5 ml LB media with a colony of transformed C41(DE3) 
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cells, and incubation at 37 ⁰C, shaking at 150 g for ~16 hours. The starter cultures were 
transferred to 4×500 ml LB media, and incubated at 37 ⁰C, shaking at 150 g until OD600 ~0.6. 
Following this, overexpression of the recombinant protein was induced with 1 mM IPTG, and 
the protein was expressed at 37 ⁰C, shaking at 150 g for ~5 hours. At the end of this period 1 
ml aliquots were collected from each flask and cells from these aliquots were harvested and 
lysed with BugBuster® reagent, and the insoluble extracts were collected by centrifugation. 
The supernatants were discarded and pellets collected and screened for protein expression 
since the MCs are expected to express into inclusion bodies. Protein expression was screened 
by 12% SDS-PAGE and the gel was stained with Coomassie brilliant blue for visualization 
(Figure 4-3). Bands of relatively high intensity were observed just below the 40 kDa marker, 
which is close to the expected size of the protein of ~35kDa. Cells were harvested from the 
rest of the culture by centrifugation, discarding the supernatants and collecting the pellets. 
These were stored at -20 ⁰C until further use. 
 
Figure 4-3: Expression of the SCL25A16 protein in E. coli C41 (DE 3) cells.  The insoluble extracts were 
harvested from cell lysates and screened for overexpression of SLC25A16. M denotes the molecular weight marker 
(Broad range Page ruler, NEB). Expression was induced with 1 mM IPTG (concentration indicated at the bottom 
panel). Protein expression was screened by 12% SDS/PAGE and the gel was stained with Coomassie brilliant 
blue.  
The pellets were thawed at 4 ⁰C and resuspended in lysis buffer containing Triton X-114 
detergent. The cells were lysed by sonication, and the insoluble extracts were collected by 
centrifugation. The supernatant was discarded and the pellet was resuspended by pulse 
sonication for 3×30 s with more detergent.  Following this, the suspension was subjected to 
another centrifugation cycle. The process was repeated until the pellet was homogenous (i.e.: 
no “halo” around the pellet). Two intense bands between 30 and 40 kDa were subsequently 
observed upon SDS-PAGE analysis (Figure 4-4). The smaller one of the two bands was 
postulated to be an E. coli membrane protein which is a common contaminant in purification 
of recombinant membrane proteins184,185. The protein suspension was the subjected to 
ultracentrifugation on a density gradient to harvest what would presumably be “homogenous” 
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inclusion bodies. Unfortunately, the preparation still contained contaminants. As stated above, 
these contaminants are presumed to be endogenous E. coli membrane proteins that are quite 
difficult to remove at this point in the purification process.  Such contaminants are usually a 
result of suboptimal cell lysis. A French press is a more efficient technique for cell lysis, but 
we did not have access to such an instrument at the time of performing this study. Therefore, 
we opted to continue with the partially pure preparation to perform an initial characterization. 
 
Figure 4-4: Purification of SLC25A16 inclusion bodies. The inclusion bodies were harvested by progressive 
wash steps with Triton X-114. The insoluble extract was collected by centrifugation at each step. The purification 
was screened by 12% SDS-PAGE and the gel was stained with Coomassie brilliant blue.  
The process of resolubilization involves protein denaturation by progressive addition of a 
detergent. Up to 2% of sarkosyl was added to the SLC25A16 preparation, as its inclusion 
yields the most satisfactory outcome relative to other detergents185. Following resolubilization, 
the detergent is usually removed by centrifugation. Subsequently, 12% SDS-PAGE was 
performed to confirm presence of the resolubilized protein in the supernatant. The resulting 
gel is shown in Figure 4-5, in which two bands can be seen, one 30 kDa in size, and the other 
just below 40 kDa in the resolubilized fraction. These are at the same positions previously 
observed in the purification evaluation gel. These bands were presumed to be the target 
protein together with the E. coli membrane protein contaminant. Due to the difficulties 
encountered in removing the endogenous protein contaminants and the low overall yield, we 
decided to proceed to reconstitute the resolubilized protein into liposomes.  
The now denatured protein folds back into its native conformation during reconstitution and 
the process must occur gradually. This was done by preparing a lipid suspension of α-
phosphatidylcholine in the presence of small amounts of detergent (~2% Triton X-114), then 
systematically adding cardiolipin and the resolubilized protein. Excess protein and detergent 
was then removed by slow passage through an Amberlite-XAD column prepared in 
house184,185. This process was repeated about 13 times. Following this, the suspension was 
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subjected to freeze-thaw cycles and extrusion to promote formation of unilamellar 
proteoliposomes containing the SLC25A16 in a presumably functional state.  
 
Figure 4-5: 12% SDS-PAGE of resolubilized SLC25A16 extracts. Inclusion bodies containing SLC25A16 were 
purified by progressive addition of Triton X-114. Following this, the inclusion bodies were resolubilized with ~2% 
sarkosyl. M denotes the broad range molecular weight marker (Broad range page ruler, NEB). The gel was stained 
with Coomassie brilliant blue. 
4.2.2 Functional characterization of SLC25A16: Efflux measurements with PantSH, 
P-PantSH and dePCoA 
For functional characterization of SLC25A16, we prepared proteoliposomes loaded with 
dePCoA, PantSH or P-PantSH, respectively. The efflux of respective molecules from the 
liposomes was measured using the discontinuous CPM-based assay described in chapter 2 
(Figure 4-6).  The diffusion rate of the free metabolite was not measured as it was already 
demonstrated that all three molecules can freely diffuse over the dialysis membrane. 
Furthermore, the time intervals used here are much shorter than the intervals used to measure 
passive diffusion as was done in the studies described in chapter 3. This was done due to the 
expectation—informed by previous studies—that protein-mediated membrane transport would 
occur more rapidly than permeation by passive diffusion.   
Apart from measuring the efflux of the thiolated molecules of interest directly, we were also 
interested in establishing if this efflux was affected (positively or negatively) by the presence 
of adenosine nucleotides. This interest was based on the findings that other SLC25 carriers 
often use counter-exchange mechanisms for transport. Consequently, the efflux of the CoA 
biosynthetic precursors were measured from the proteoliposomes both in the absence and 
the presence of either ATP or ADP (Figure 4-7). Any changes in the observed efflux rate could 
then be attributed to the presence of the nucleotide, indicating a counter-exchange or other 




Figure 4-6: Work flow for measuring efflux from SLC25A16 proteoliposomes. Proteoliposomes were prepared 
by in the presence of a detergent by the extrusion. These were prepared with either PantSH, P-PantSH or dePCoA 
loaded in the intraliposomal cavity. The efflux was the measured by the discontinuous liposomal assay for 
permeability measurement described earlier. 
The results show rapid efflux of dePCoA from the liposomes in the absence of the nucleotides. 
The presence of either ATP or ADP does not seem to affect the efflux rate of this molecule 
(Figure 4-7 A). The CPM adducts formed with the respective thiol molecules have varying 
fluorescence emission signals and this is the reason for difference in fluorescence intensity 
between Figure 4-7 A to C. PantSH efflux could also be observed in the absence of 
nucleotides, although this was not to the same extent as for dePCoA. However, ATP and ADP 
seemed to inhibit the efflux of this molecule (Figure 4-7 B). On the other hand, no efflux was 
observed for P-PantSH unless ADP was present (Figure 4-7 C). 
The lack of distinction in dePCoA in the presence of absence of adenosine nucleotides is in 
line with the view that the transporter recognises the adenylyl moiety of dePCoA for transport. 
Conversely, the diminished efflux of PantSH in the presence of either ATP or ADP suggests 
that these molecules compete for the same binding site on the transporter, and that the 
transporter possibly has stronger affinity for the adenosine nucleotides resulting in inhibition 
of PantSH efflux. On the other hand, the ADP-dependent P-PantSH efflux suggests that there 
may be a counter-exchange transport mechanism in its case. However, this cannot be 







Figure 4-7: Efflux measurements of PantSH, P-PantSH and dePCoA from SLC25A16 proteoliposomes. The efflux of dePCoA, PantSH, P-PantSH from SLC25A16 
proteoliposomes was measured in the absence (black), as well as presence of 3 mM of either ATP (red) or ADP (green).Linear curve fits were performed on sigmaplot-14.0, and 




This study provided the first data on the substrate specificity of the human SLC25A16 carrier. 
In particular, we demonstrate efflux of that dePCoA regardless of the presence of any external 
nucleotides. In addition, the observed differences in efflux of P-PantSH in the presence of 
ADP indicates that this molecule of interest likely occurs by a counter-exchange mechanism. 
This change would not have occurred if the observed efflux was due to passive diffusion, or 
due to non-specific leakage. Furthermore, the main component of the liposomes used in this 
study is phosphatidylcholine, which was also the main constituent of the eukaryotic membrane 
model described in chapter 3. P-PantSH was shown to efficiently cross the latter by passive 
diffusion. Therefore, the observed dependence on ADP of P-PantSH efflux in the current 
study, is evidence that the two process are distinct from each other. However, a control 
experiment using liposomes devoid of a transporter would have been ideal to ascertain that 
the observed efflux is true result of protein-mediated membrane transport. 
Finally, our results indicate that the protein purification method should be optimised to improve 
confidence in the observed results. As stated, a more efficient lysis method would ensure 
minimal contamination. Furthermore, the identity of the protein could be confirmed by mass 
spectrometry or western blot since SLC25A16 antibodies are commercially available. Amino 
acid analysis could also be performed to determine absolute protein concentration in purified 
inclusion bodies – this would simplify the process of quantifying resolubilized protein extracts, 
which will in turn be useful for the purposes of reporting kinetic data. Microscopy techniques, 
which were instrumental for confirming encapsulation efficiency of the liposomal preparation 
described in chapter 2 and 3, could also be useful for confirming protein reconstitution.  
4.4 Conclusion 
We were able to demonstrate transport kinetics of SLC25A16 with the discontinuous liposomal 
assay describe in chapter 2, which is further evidence of the versatility of this assay. We also 
provide first evidence that SLC25A16 may be a P-PantSH/ADP transporter. This supports the 
proposition that P-PantSH plays a regulatory role in maintenance of subcellular CoA pools 
since this transporter is implicated, at least in the regulation of mitochondrial CoA levels.  
4.5 Materials and methods 
Agar, Tryptone, Sodium chloride (NaCl), Yeast extract, , Sodium dodecyl sulphate (SDS), , 
Tris, HCl, Ethylenediaminetetraacetic acid (EDTA), Dithiothreitol (DTT), sucrose, Tris(2-
carboxyethyl)phosphine hydrochloride (TCEP), Sodium sulphate (Na₂SO₄), CPM, 3'-
Dephospho Coenzyme A (dePCoA), Amberlite®-XAD®, Triton-X114™, Adenosine 5'-mono-
phosphate (AMP), Adenosine 5'-diphosphate (ADP), Adenosine 5'-triphosphate (ATP) and 
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thiamine pyrophosphate (TPP) all had a purity of 95 % or higher and were purchased from 
Sigma-Aldrich, Germany. 30% acrylamide monomer solution for electrophoresis (PAGE) was 
also purchased from Sigma-Aldrich. Methanol (99% Purity for HPLC) was purchased from 
Merck, Germany. Coomassie® Brilliant blue R 250 was purchased from Merck, Germany. 
Glass Pasteur pipettes and black 96 well plates were purchased from Lasec. Sephadex G-75 
was from (GE Healthcare, USA). The unstained broad range page ruler (P7717) was 
purchased from NEB (U.S.A).The Beckman J-26 XPI centrifuge and Optima L-80 XP 
ultracentrifuge were used to perform the centrifugation steps. 
4.5.1 Sub-cloning and expression of SLC25A16 protein 
The gene construct for SLC25A16 cloned into a high copy pRUN plasmid was a gift from G. 
Fiermonte, Bari University – Italy. Chemically competent E. coli C41 (DE3) cells were 
transformed with the plasmid using heat shock. The cells were then transferred to  LB-Agar 
solid media (20 g agar, 10 g tryptone, 10 g NaCl and 5 g yeast extract  1 L MilliQ water), and 
incubated at 37 ⁰C for ~16 hours. One colony was picked from the agar plate and transferred 
to 2 × 5 mL LB-media (10 g tryptone, 10 g NaCl and 5 g Yeast extract 1 L MilliQ water). This 
was also incubated at 37 ⁰C for ≈16 hours for maximum growth of the transformed cells. These 
starter cultures were then transferred to 2 × 1 L LB media and incubated at 37 ⁰C, shaking at 
150 g until the OD600 ~0.6–0.8. Following this, 1 mL aliquots were collected as pre-induction 
controls from each flask. Overexpression of the recombinant protein was induced with IPTG 
to the final concentration of 0.5 and 1 mM for each respective flask. The protein was expressed 
at 37 ⁰C, shaking at 150 g for 16–20 hours, but two aliquots were collected at 3 hours post-
induction as well as at the end of the incubation period. All the aliquots collected were treated 
with bug buster reagent to lyse the cells. The insoluble cell extracts were harvested by 
centrifugation and screened for protein expression with 12% SDS-PAGE. Cells were 
harvested from the rest of the cultures by centrifugation at 8 000 g, 4 ⁰C for 20 minutes in a 
fixed angle rotor (Beckman JA-10). The supernatant was discarded, and the pellet collected 
and stored at -20 ⁰C until further use. 
4.5.2 SDS-PAGE 
The expression and purification evaluation of the proteins were achieved The separation gel 
solution was prepared with Acrylamide/bis (30% 37.5:1, Sigma-Aldrich) and Sodium dodecyl 
sulphate (SDS) 10 % (w/v) in 1.5 M Tris-HCl at pH 8.8. The polymerization reaction was 
initiated with Ammonium persulfate (APS), 10% (w/v) and N,N,N′,N′-tetramethylethylene-
diamine (TEMED) according to the method described in186. The solution was prepared as 
indicated in Table 4-1. 
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Table 4-1:  The 12% separation gel solution 
Component Volume (mL) 
Water  1.4 
Acrylamide/bis (30%) 3.3 
1.5 M Tris-HCl, pH 8.8 2.5 
SDS (10% w/v) 0.1 
APS (10% w/w) 0.1 
TEMED 0.032 
 
The stacking solution was prepared as indicated in Table 4-2. 
Table 4-2: The 4% stacking gel solution 
Component Volume (mL) 
Water  6.1  
Acrylamide/bis (30%) 1.3 
0.5M Tris-HCl, pH 6.8 2.5 
SDS (10% w/w) 0.1 
APS (10% w/w) 0.01 
TEMED 0.1 
 
4.5.3 Coomassie brilliant blue stain 
All the SDS-PAGE gels were stained with Coomassie brilliant blue stain according to a 
protocol described by 187. The following four solutions with varying concentrations of the 
Coomassie brilliant blue stain were used to stain each gel: 
Solution A: Isopropanol 25% (v/v), Acetic Acid 10% (v/v), Coomassie R-250 0.05% (w/v). 
Solution B: Isopropanol 10% (v/v), Acetic Acid 10% (v/v), Coomassie R-250 0.005% (w/v). 
Solution C: Acetic Acid 10% (v/v), Coomassie R-250 0.002% (w/v). 
Solution D: Acetic Acid 10% (v/v). 
Each gel was first immersed in solution A, heated in the microwave for 20 seconds, and then 
placed on an orbital shaker for 5 minutes. The solution was then discarded and the gel rinsed 
with MilliQ water. The gel was then immersed in solution B and then subjected to the same 
process this continued progressively until the gel was finally immersed in Solution D which is 
the “destaining” solution. 
4.5.4 Purification of SLC25A16 inclusion bodies 
The SLC25A16 inclusion bodies were purified based on the method described by 185.The lysis 
buffer was prepared as follows: 1% (v/v) Triton-X114, 10 mM Tris-HCL, pH 7.00, 0.1 mM 
EDTA and 1 mM DTT. Specifically, a 10 × stock solution of this buffer was prepared, which 
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was then diluted prior to each preparation. A previously prepared protein pellet was thawed at 
room temperature. This was resuspended with 20 mL of the lysis buffer described above. The 
cells were lysed with 5 sonication cycles with 30 sec pause between each. The inclusion 
bodies were harvested by centrifugation at 20 000 g for 15 min in a fixed angle rotor (Beckman 
JA-25.50). The supernatant was discarded and the pellet resuspended in another 20 mL of 
lysis buffer. The sonication and centrifugation cycles were repeated six times as described 
above. The pellet from the final cycle was resuspended in 5 ml of lysis buffer without Triton X-
114 and stored at 4 ⁰C until further use. 
A sucrose density gradient was prepared as follows: 4 mL of 70% (w/v) sucrose, 9 mL 53% 
(w/v) sucrose and 4.5 mL 40% (w/v) sucrose. Each solution was prepared with MilliQ water. 
The gradient was loaded and allowed to stand for about 12 hours to settle. The inclusion 
bodies were then harvested by placing 2 mL of the suspension onto the gradient bed. 
Centrifugation was performed at 141 000 g for 5 hours in a preparative ultracentrifuge to 
fractionate the inclusion bodies. The target protein separated as a brown-gold disk in between 
the 70 and 53% layers. It was collected by further centrifugation at 13 000 g for 15 minutes in 
2 mL reaction tubes. The supernatant was discarded and the pellet resuspended in 2mL of 1 
M NaCl, 10 Mm Tris-HCL, pH 7.00, 1 mM DTT, 0.1 mM EDTA. Centrifugation was performed 
again at 13 000 g for 15 minutes. The pellet resuspension and centrifugation was repeated 
three times to remove excess sucrose. Following this, the pellet was resuspended in MilliQ 
water and the centrifugation step was repeated. The resuspension in water and centrifugation 
was also repeated several times to remove the excess NaCl. Finally, the pellet was 
resuspended in 1 mL Tris-HCl, pH 7.00, 10 mM Na₂SO₄, 1 mM DTT, and 0.1 mM EDTA. The 
suspension was then aliquoted into 100 μL portions and flash frozen in liquid nitrogen and 
store at -80 °Ϲ.  
4.5.5 Resolubilization 
One 100 μL aliquot of inclusion bodies was thawed on ice. Then, 60 μL of resolubilization 
buffer containing (1.67% sarkosyl, Tris-HCL, pH 7.00, 0.1 mM EDTA, and 1 mM DTT) was 
added to the aliquot. The suspension was then cooled on ice for another 5 minutes. The 
protein was resolubilized by pipetting up and down on ice for about 10 minutes or until the 
solution was clear. The solution was then diluted with 500 μL water in a stepwise manner (this 
is: 100 μL at a time). The sarkosyl was removed by centrifugation at 12 000 ×g for 10 minutes 
and the solubilized protein was collected in the supernatant. 
4.5.6 Reconstitution 
Liposomes were prepared from α-phosphatidylcholine by sonication for 20 seconds. The 
sonication was repeated 5 times with 30 second pause between cycles. The following 
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components were then added to the liposomal suspension: 60 μL soluble protein, 3% Triton 
X-114, 10 mM Tris-HCL, pH 7.00, 0.1 mM EDTA and 5 mM  dePCoA (or P-PantSH) + 7.5 Mm  
TCEP. Following this, 500 μL of 2 mg/ml cardiolipin were added. The suspension was then 
mixed by vigorous vortexing. It was then flash frozen in liquid nitrogen and thawed at ~ 16 °Ϲ 
in a water bath. This cycle was repeated 5 times to promote formation of unilamellar vesicles. 
The unilamellar vesicles were then prepared by performing 20 extrusion passes on the Avanti 
Polar Lipids® mini-extruder fitted with 2 × polycarbonate filters. 
4.5.7 Proteoliposome purification 
An Amberlite-XAD column was prepared as follows: A 2 mL glass Pasteur pipette was sealed 
with cotton wool. Following this, 600 mg of Amberlite beads were placed in the column. The 
column was then washed with 13 passages of methanol (Merck, Germany) and then left in the 
methanol overnight. The methanol was then washed off with Tris-HCL buffer described in 
4.5.7. Thereafter 1 ml of the reconstitution mixture was then passed through the column and 
eluted with the solubilization buffer. The first two 500 μL fractions were collected. These were 
pooled and the passage was repeated about 5 more times. Following this, excess metabolite 
was removed by size exclusion on a Sephadex G-75 (Amerscham, GE Healthcare) column 
prepared in house. The beads were hydrated with 10 mM Tris-HCL, pH 7.00, 0.1 mM EDTA 
and 5 mM NaCl +7.5 mM TCEP. Excess moisture was removed and the slurry was packed in 
a 5 mL syringe column sealed with cotton wool.  The column was placed in a 15 mL centrifugal 
tube and residual buffer was removed by centrifugation at 3 000 g for 5 minutes. The flow-
through was removed and the proteoliposomes suspension was loaded onto the column bed. 
The “pure” liposomes were then harvested by centrifugation at 1000 g for 5 minutes and 
collected in the flow through. 
4.5.8 Efflux measurements 
Efflux of dePCoA was measured by hydrating a dialysis unit with 900 μL of 10 mM Tris-HCl, 
pH 7.00 with 0.1 mM EDTA. Subsequently, 200 μL of the proteoliposome suspension was 
placed inside the dialysis unit and efflux was monitored by collecting 20 μL aliquots at 5 minute 
intervals for 25 minutes. Solutions of AMP, ADP, ATP and TPP were prepared to a final 
concentration of 100 mM each. Four dialysis unit were then hydrated with 4 × 900 μL of 10 
mM Tris-HCl, pH 7.00 with 0.1 mM EDTA. The proteoliposome was added to each dialysis 
unit this time with 0.5 mM of respective adenosine nucleotide, to the final concentration of 200 
μL. The efflux of dePCoA in the presence of the adenosine nucleotides was then measured 
by collecting 20 μL aliquots of each dialysate at 5 minute intervals for 25 minutes. The process 
was repeated for 3 mM and 6 mM adenosine nucleotides. Each 20 μL aliquot collected was 
transferred to a black 96-well plate to which 170 μL of Tris-HCl pH 7.00 and 10 μL of CPM 
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(100 μM) was added. The fluorescence intensity was then measured at λex = 387 and λem = 
465 nm of each aliquot such that the efflux could be reported as a fluorescence intensity time 
course. The slope of each time course was obtained from a linear curve-fit performed on the 
Sigma-plot version 14.0 software. This was such that the efflux rate was slope ± standard error 




Chapter 5: Concluding remarks and future studies 
Membrane permeability of small molecules is an important but often neglected part of drug 
discovery. This can mainly be attributed to a lack of adequate investigational tools. Therefore, 
we described a discontinuous assay for measuring membrane permeability of CoA-related 
small molecules in an effort to address this limitation in the context of thiolated molecules like 
CoA. In addition, we were able to demonstrate the versatility of this assay setup by expanding 
it to molecules with other functionalities such as phosphorylated and non-phosphorylated 
pantothenate analogues. This was achieved by modification of the detection method used to 
quantify the molecules in question. Moreover, we demonstrated that the assay is also 
amenable to the study of membrane carriers, and was therefore applied to the study of a 
mitochondrial membrane carrier.  
The most reproducible outcomes were observed with the CPM-based fluorescence detection 
method used to determine the diffusion rates of thiolated molecules. This method enables 
direct measurement of the molecule in question, while the other two methods used entailed 
measurement of a secondary factor related to the concentration of the molecules of interest. 
Unfortunately, this resulted in pronounced variability which made the measurements less 
reliable. This difference in reproducibility between the CPM-based  and the coupled enzyme 
assay-based measurements is an indication that it would be worthwhile to identify other  
chromophores that work by a mechanism similar to that of CPM but recognise different 
reactive groups like the phosphate or amine moiety. Moreover, techniques like LC-MS could 
also be considered for more accurate measurements of the diffusion rates, since these are 
more sensitive than standard spectroscopic techniques. However, the drawback with such 
techniques include the cost implications. 
The second aim of the study was to identify the molecular determinants that confer 
permeability by passive diffusion in pantothenate analogues. This was achieved by measuring 
membrane permeability across in vitro models of mammalian and bacterial membrane 
models. This was done in an effort to find out if there was any correlation between permeability 
and structure of the molecule of interest. We investigated the role of membrane composition 
in the ability of the molecules to cross membranes by passive. Unfortunately, no direct 
correlation was found between the permeability and the molecule’s structure. However, the 
relevance of the phospho-pantoyl moiety in promoting permeability could at least be inferred 
from the data. On the other hand, the membrane fluidity analysis indicates that the 
permeability of P-PantSH more likely correlates with the fluidity of the membranes in question. 
This in turn suggests that manipulation of membrane composition to affect membrane fluidity 
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may offer a new mechanism to regulate the maintenance of CoA levels from exogenous 
sources. 
Our final objective was to characterize a mitochondrial carrier associated with regulation of 
CoA – SLC25A16. Two other transporters with affinity towards CoA and dePCoA have been 
identified. However, in both cases the affinity was determined using homo-exchange 
experiments which measure the exchange of a radiolabelled molecule for the non-
radiolabelled form. On the other hand, our results constitute the first report of the transport of 
a CoA-related molecule through direct measurement of its efflux. Specifically, dePCoA efflux 
was observed from SLC25A16 regardless of the presence of adenosine nucleotides, while the 
presence of ADP was required for P-PantSH efflux.  Since this transporter is associated with 
regulation of mitochondrial CoA, its demonstrated affinity towards dePCoA and P-PantSH 
supports the view that homeostatic regulation of CoA is mediated by CoA biosynthetic 
intermediates in eukaryotic cells. This is useful information regarding the transporter and CoA 
homeostasis in general; however, a more comprehensive characterisation that includes other 
potential substrates would provide a more complete picture. The preparation of the 
proteoliposome also has to be optimised to eliminate doubt regarding the observed outcomes 
related to the presence of bacterial contaminant proteins.  Furthermore, it may be worthwhile 
to re-visit the other two MCs associated with CoA transport—SLC25A17 and SLC25A42—to 
understand the involvement of all three in this process. 
Taken together, these findings provide evidence that P-PantSH may indeed be a nexus 
metabolite of CoA metabolism, and this may have important implications for the development 
of drugs that target CoA biosynthesis and utilization. This may be in the context of human 
diseases for the treatment of (or delaying the onset of) neurodegenerative diseases, or 
alternatively as antimicrobials for the treatment of infectious diseases. Therefore, in order to 
improve our insight regarding the aspects of membrane permeability and transport of CoA as 
addressed in this dissertation, we have set out the following objectives for future studies:  
1. Since the importance of the phospho-pantoyl moiety in promoting membrane 
permeability is suggested by our findings, the membrane permeability measurements 
of the phosphorylated and non-phosphorylated pantothenate analogues should be 
repeated with more sensitive detection methods in an effort to identify such a structure-
permeability relationship. 
2. To verify the correlation between membrane fluidity and permeability observed for P-
PantSH, the membrane fluidity should also be examined using other biophysical 
techniques, such as differential scanning calorimetry (DSC) and SAXS, and the results 
compared to the permeability outcomes. This work should ideally be done by using a 
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range of liposomal formulations that differ in lipid identity and fluidity from those 
described in this study. 
3. To optimise the purification of SLC25A16 and verify its identity with mass spectrometry, 
and to directly confirm its reconstitution in proteoliposomes with a multiplatform 
technique such as correlated light and electron microscopy (CLEM) that uses different 
detection techniques to create contrast between particles in a single micrograph. 
4. The crystallization of SLC25A16 nano-disks to study the binding/substrate recognition 
site of the carrier protein – this will aid in identifying the true substrate for this 
mitochondrial carrier. 
5. To perform the same analysis done on SLC25A16 on SLC25A42 and SLC25A17 using 
the membrane permeability assay described in chapter two, so as to directly confirm 
the transport of CoA and CoA-related metabolites by these carriers. This will 
complement the results achieved in previous studies that inferred their transport from 
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